

1

Towards Enhanced AMR Monitoring under the Recast Urban Wastewater Treatment Directive (EU) 2024/3019

A Stocktaking Review of EU Member States' Studies and a Proposal Outline for a Quantitative PCR-based Monitoring



2025

Tavazzi, S., Comero, S., Hirvonen, A., Panzarella G., Mariani, G., Maffettone, R., Casado Poblador, T., Bausa Lopez, L., Marchini, A., Petrillo, M., Querci, M., Glowacka, N., Gawlik, B.M.

2 This document is a publication by the Joint Research Centre (JRC), the European Commission's science and knowledge
3 service. It aims to provide evidence-based scientific support to the European policymaking process. The contents of this
4 publication do not necessarily reflect the position or opinion of the European Commission. Neither the European
5 Commission nor any person acting on behalf of the Commission is responsible for the use that might be made of this
6 publication. For information on the methodology and quality underlying the data used in this publication for which the
7 source is neither Eurostat nor other Commission services, users should contact the referenced source. The designations
8 employed and the presentation of material on the maps do not imply the expression of any opinion whatsoever on the part
9 of the European Union concerning the legal status of any country, territory, city or area or of its authorities, or concerning
10 the delimitation of its frontiers or boundaries.

11 **Contact information**

12 Name: Bernd M. Gawlik
13 Address: Via Enrico Fermi 2749 I-21027 Ispra/Italy
14 Email: bernd.gawlik@ec.europa.eu
15 Tel.: +39 0332 78 9487

16 **EU Science Hub**

17 <https://joint-research-centre.ec.europa.eu>

18 JRC142236

19 Luxembourg: Publications Office of the European Union, 2025

20 © European Union, 2025



21 The reuse policy of the European Commission documents is implemented by the Commission Decision 2011/833/EU of 12
22 December 2011 on the reuse of Commission documents (OJ L 330, 14.12.2011, p. 39). Unless otherwise noted, the reuse of
23 this document is authorised under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence
(<https://creativecommons.org/licenses/by/4.0/>). This means that reuse is allowed provided appropriate credit is given and
any changes are indicated.

24 For any use or reproduction of photos or other material that is not owned by the European Union permission must be
25 sought directly from the copyright holders.

26 The European Union does not own the copyright in relation to the following elements:

- 27 - Cover page background image, European countries 3d illustration ©koya979 / stock.adobe.com
- 28 - Cover page background image, Aerial view of a large industrial water treatment plant ©zulie / stock.adobe.com

29 How to cite this report: European Commission: Joint Research Centre, Tavazzi, S., Comero, S., Hirvonen, A., Panzarella, G.,
30 Mariani, G., Maffettone, R., Casado Poblador, T., Bausa Lopez, L., Marchini, A., Petrillo, M., Querci, M., Glowacka, N. and
31 Gawlik, B.M.,
32 *Towards Enhanced AMR Monitoring under the Recast Urban Wastewater Treatment Directive 2024/3019*; Publications
33 Office of the European Union, Luxembourg, 2025, JRC142236.

34 **Contents**

35 Abstract 4

36 Authors 6

37 Acknowledgements 7

38 Disclaimer 8

39 Policy context..... 9

40 Key conclusions..... 10

41 Structure of the report 11

42 1. Introduction..... 13

43 2. Methods 15

44 3. Findings..... 16

45 Sampling and analytical methods..... 16

46 ARGs monitored 18

47 Descriptors for monitoring ARGs..... 23

48 4. Recent AMR monitoring initiatives..... 24

49 4.1. “WHO Integrated Global Surveillance on ESBL-producing *E. coli* (Tricycle Protocol) 24

50 4.2. EU-WISH 25

51 5. Collaborative Frameworks in Antimicrobial Resistance Monitoring: The Roles of Eionet and

52 TATFAR..... 28

53 5.1 European Environment Information and Observation Network (Eionet)..... 28

54 5.2 The Transatlantic Taskforce on Antimicrobial Resistance (TATFAR)..... 30

55 6. International standardisation 32

56 7. National Obligations for AMR Monitoring in Aquatic Systems: EU-27 Comparative Analysis..... 34

57 8. Analytical methods for monitoring AMR in water: strengths and limitations..... 35

58 9. Discussion 37

59 9.1. Preliminary method proposal for AMR monitoring in urban wastewater..... 40

60 9.2 Cost considerations 43

61 9.3 Additional considerations..... 45

62 Handling of wastewater samples 45

63 9.4 The value of other technologies in AMR monitoring..... 45

64 Harmonising metagenomic sequencing 46

65 Rise of artificial intelligence (AI) 47

66 Developments in quality assurance control (AQC)..... 47

67 10.Next steps 48

68 List of abbreviations and definitions..... 49

69 Annexes 52

70 Annex 1: Prompt template for data extraction 52

71 Annex 2: Summary of extracted data from reviewed literature. Table A1. Summary of extracted
72 data for EU countries including references, sampling and analytical methods, targeted ARGs,
73 standardisation status, and monitoring descriptors..... 55

74 Annex 3: National Obligations for AMR Monitoring in Aquatic Systems: EU-27 Comparative
75 Analysis Table A2. Overview of national obligations and monitoring practices for antimicrobial
76 resistance (AMR) in aquatic systems across EU-27 member states. The dataset may not reflect all
77 ongoing initiatives due to variability in national reporting and evolving legislations. 61

78 Annex 5: Cost estimation and evaluation for monitoring AMR in wastewater 79

79

80

81 **Abstract**

82 Antimicrobial resistance (AMR) is an escalating environmental and public health challenge, increasingly
83 associated with the acquisition and dissemination of antibiotic resistance genes (ARGs) through urban
84 wastewater systems. In response, the recast Urban Wastewater Treatment Directive (EU) 2024/3019
85 (UWWTD) mandates the establishment of harmonised minimum sampling frequencies and
86 standardised methodologies for AMR monitoring across EU Member States. Specifically, UWWTD
87 requires monitoring for AMR at those UWWTP's serving agglomerations of 100,000 population
88 equivalents (p.e.) and above (currently numbering 1,287 UWWTPs across the EU, based on latest
89 reporting).

90 This report reviews current AMR monitoring practices in urban wastewater across EU Member States
91 to enhance data harmonisation and cross-national comparability, thereby improving the
92 characterisation of AMR occurrence and significance in urban wastewater systems.
93 Contributions from 12 Member States, encompassing 109 references, were analysed, revealing
94 substantial heterogeneity in sampling designs and analytical techniques.

95 Culture-based methods remain prevalent, yet molecular approaches, particularly quantitative PCR
96 (qPCR) and digital droplet PCR (ddPCR), are widely adopted due to their high sensitivity and specificity
97 for detecting targeted ARGs. A total of 189 ARG targets were identified across 17 water matrices,
98 highlighting the complexity and diversity of AMR profiles in water-based environmental matrices.
99 Building on this evidence, this report proposes a targeted qPCR-based approach as the preferred
100 methodology for routine AMR surveillance in urban wastewater. Compared to other potential
101 methods, such as metagenomic analysis which provides broad resistome insights but remains
102 resource-intensive, qPCR offers a cost-effective, scalable, and technically accessible solution, making
103 it highly suitable for harmonised implementation across EU Member States.

104 A panel of 24 ARGs + 1 additional genetic target (*int1*) in urban wastewater was defined through a
105 structured process combining: (i) consultation with EU Member States and analysis of the references
106 they submitted; (ii) review of ongoing standardisation activities (CEN, ISO, ASTM) and of reports
107 prepared by relevant expert networks (WHO, Eionet); (ii) input provided by JRC scientists and research
108 partners; and (iv) a comprehensive assessment of the scientific literature.

109 The final selection was cross-checked against WHO List of Medically Important Antimicrobials (MIA
110 List), the WHO Model List of Essential Medicines (EML List), and the WHO Bacterial Priority Pathogens
111 List 2024 (2024 BPPL), as well as environmental AMR monitoring studies (such as the *Pilot study on
112 antimicrobial resistance* (April, 2025) from the Eionet Working Group, ensuring relevance from both
113 public health and environmental perspectives. The resulting panel reflects a balanced representation
114 of clinically important and environmentally traceable resistance determinants, ensuring that the most
115 relevant aspects of AMR are captured through a One-Health aligned approach, while acknowledging
116 that the majority are antibiotic resistance genes – an emphasis justified by their central role in human
117 health and environmental dissemination.

118 The suggested monitoring design foresees monthly sampling of both influent and effluent at urban
119 wastewater treatment plants (UWWTPs), corresponding to 24 samples per facility per year. This
120 frequency is designed to capture seasonal fluctuations in population behaviours, antimicrobial usage
121 and patterns influencing the occurrence of AMR, while not entailing excessive costs.
122 The recast Urban Wastewater Treatment Directive (UWWTD), requires monitoring for AMR at those
123 UWWTPs serving agglomerations of 100,000 population equivalents (p.e.) and above (currently
124 numbering 1,287 UWWTPs across the EU, based on latest reporting).

125 This report further recognises that AMR monitoring in environmental matrices is a rapidly evolving

126 field. Important gaps remain, particularly concerning resistance mechanisms beyond antibiotics, which
127 may have significant implications for One Health.

128 To address these uncertainties, this report recommends further research and validation of additional
129 AMR determinants, supported by other potential methods such as metagenomic sequencing, here
130 considered as a voluntary complementary tool. These approaches can capture the broader resistome,
131 detect emerging genes and inform the progressive refinement of the proposed qPCR panel.

132

133 **Authors**

134 Tavazzi, S., Comero, S., Hirvonen, A., Panzarella, G., Mariani, G., Maffettone, R, Casado Poblador, T.,

135 Bausa, L., Marchini, A., Petrillo, M., Querci, M., Głowacka, N., Gawlik, B. M.

136 **Acknowledgements**

137 We acknowledge the invaluable support of the following experts in reviewing and refining the final
138 version of this report. While these experts reviewed the document for scientific validity, the content
139 does not necessarily reflect their positions and should not be interpreted as an endorsement on their
140 behalf.

141

142 *Public Health Angle:*

143 - Jörg B. HANS, RKI, DE

144 - Heike SCHMITT, RIVM, NL

145

146 *Environmental Angle:*

147 - Despo FATTA-KASSINOS, UCY, CY

148 - Edward TOPP, INRAE, FR

149 - Adriana KROLICKA, NORCE RESEARCH, NO

150

151 *Private Sector Angle:*

152 - Windi MUZIASARI, RESISTOMAP, FI

153

154 *General Consultancy WWTP Engineering, TATFAR Support:*

155 - Kyriakos MANOLI, ENVIROMUSE CONSULTING, CA

156 **Disclaimer**

157 *Artificial intelligence (AI) tools, including the GPT@JRC tool (utilising LLaMA 3.3 70B Instruct*
158 *and GPT-4o), were used to assist with data extraction and summarisation.*

159 *This document was reviewed in its final stages with the assistance of Grammarly®.*
160 *The feedback provided by Grammarly® was carefully evaluated and used as a basis for revising the*
161 *writing. All revisions were made using the authors own words and expressions to ensure originality and*
162 *authenticity.*

163 *It is important to note, though, that despite the assistance from these AI resources, the core content*
164 *and texts within these proceedings are the result of genuine human intellectual efforts.*

165 **Policy context**

166 The establishment of comprehensive surveillance frameworks under the One Health approach is
167 crucial for enhancing public health protection, enabling more effective monitoring and ensuring timely
168 response to health threats in an increasingly interconnected world. Urban wastewater is identified as
169 of great significance in understanding antimicrobial agents and the circulation of resistant bacteria in
170 the underlying population¹. Urban wastewater, originating from domestic, hospital, industrial and
171 other sources, is typically collected and treated in urban WWTPs, serving as both a reservoir and
172 transmission pathway for antibiotic resistance genes (ARGs). Discharges of treated wastewater
173 effluent and sewage sludge into the environment contribute to the spread of AMR through multiple
174 exposure routes.

175 The European Union recognises the importance of tackling the issue of AMR, as stated in the 2017
176 Communication from the Commission 'A European One Health Action Plan against Antimicrobial
177 Resistance (AMR)', and the adopted European One Health Action Plan against AMR. With the 2023
178 Council Recommendation on Stepping up EU Actions to combat AMR in a One Health approach
179 Member States are encouraged to develop integrated systems for the surveillance of AMR, including
180 in wastewater. The Recommendation recognises the role played by the presence in the environment
181 of antimicrobial residues in the emergence and spread of AMR, the levels of environmental
182 contamination and the risks posed to human health.

183 The recast Urban Wastewater Treatment Directive (EU) 2024/3019² recognises the
184 interconnectedness of human, animal, and environmental health through the One Health approach
185 and addresses the growing concern of AMR in urban wastewater. Article 17(3) of the Directive
186 empowers the European Commission to adopt implementing acts in order to establish a minimum
187 frequency of sampling and a harmonised methodology for measuring AMR in urban wastewater. The
188 Commission is to adopt these implementing acts by July 2nd, 2026. Meanwhile, Article 22(1)(h) of the
189 Directive requires Member States to report AMR monitoring results to the Commission by December
190 31st, 2030, with annual updates thereafter. Articles 17(1) and 17(2) of the Directive require Member
191 States to set up national systems for cooperation and coordination between competent authorities for
192 public health and urban wastewater treatment, facilitating early detection of public health parameters
193 including SARS-CoV-2, polio, emerging pathogens and other health determinants deemed relevant by
194 the competent authorities.

195 Joint Research Centre (JRC)'s effort has been to review literature on the topic, analyse Member States
196 submitted references, and to appraise standardisation activities undertaken by international bodies
197 such as the European Committee for Standardization (CEN), the International Organization for
198 Standardization (ISO), and the American Society for Testing and Materials (ASTM).

¹ La Rosa MC, Maugeri A, Favara G, La Mastra C, Magnano San Lio R, Barchitta M, et al. The Impact of Wastewater on Antimicrobial Resistance: A Scoping Review of Transmission Pathways and Contributing Factors. *Antibiotics*. 2025 Jan 26;14(2):131.

² European Parliament & Council. (2024). *Directive (EU) 2024/3019 of 27 November 2024 on urban wastewater treatment (recast) (Text with EEA relevance)* (PE/85/2024/REV/1). <https://eur-lex.europa.eu>

199 **Key conclusions**

200 The review of literature and data from 12 Member States revealed substantial heterogeneity in
201 sampling designs and analytical techniques for AMR monitoring in urban wastewater, highlighting the
202 urgent need for standardised methodologies. While culture-based methods remain common,
203 molecular approaches, particularly quantitative PCR (qPCR) and digital droplet PCR (ddPCR), are widely
204 adopted due to their high sensitivity and specificity and cost/effectiveness for detecting targeted
205 antibiotic resistance genes (ARGs). Nevertheless, targeted molecular approaches leave room for
206 advanced techniques such as metagenomic sequencing, which can enhance understanding of the
207 broader environmental resistome and emerging resistance mechanisms. The proposed qPCR
208 monitoring framework facilitates the collection of standardised data and metadata, providing a solid
209 foundation for understanding AMR dynamics and supporting surveillance aligned with One Health
210 objectives.

211 Next steps in support of the implementing acts under the recast UWWTD include:

- 212 1. Experimental evaluation, optimisation and validation of the proposed analytical methods
- 213 2. Consultation with expert stakeholders and Member States active in AMR monitoring.
- 214 3. JRC providing guidance and evidence to the drafting of the implementing acts.

215 **Structure of the report**

216 This document has been structured to provide a comprehensive and cohesive analysis of the
217 methodologies and challenges related to AMR monitoring. The sections are as follows:

218 1. **Introduction:** Sets the stage for the entire report, explaining the significance of monitoring
219 AMR in urban wastewater systems. It introduces key concepts such as ARGs and highlights the
220 importance of standardised methodologies. This section provides the rationale for the
221 subsequent detailed examination of European level approaches.

222 2. **Methods:** This chapter outlines the data collection procedure and analysis. Between January
223 31st and February 28th, 2025, a call for contributions on AMR monitoring in urban wastewater
224 was circulated to EU Member States and relevant networks. 109 contributions were received.
225 Additional input from CEN, ISO, and ASTM was included. The review addressed only antibiotic
226 resistance, reflecting the position of participating Member States.

227 3. **Findings:** This chapter presents the main outcomes of the review. It is organised into four
228 interrelated subchapters, each focusing on a key aspect of AMR monitoring in urban
229 wastewater. Data is summarised in Annex 1:

230 – **Sampling and Analytical Methods:** This section examines the sampling strategies and
231 analytical techniques reported in the literature shared by the different countries and
232 currently in use to monitor AMR. It highlights the diversity of approaches in practice and
233 reinforces the need for harmonised and robust monitoring strategies.

234 – **ARGs Monitored:** Building on the previous section, this part details the specific ARGs
235 identified across different monitoring efforts. It provides insight into how methodological
236 choices are often influenced by the relevance and prevalence of particular ARGs at the
237 European level.

238 – **Standardisation:** Following the discussion on methodologies and detection outcomes, this
239 section addresses the issue of standardisation. It explores national approaches to protocol
240 development and highlights existing inconsistencies, highlighting the need for improved
241 comparability of data across countries to support global AMR monitoring objectives.

242 – **Descriptors for Monitoring:** This chapter focuses on the specific metrics and parameters
243 used to quantify and interpret AMR-related data. It provides detailed insights into how
244 data is quantified and later interpreted. It complements the standardisation discussion by
245 stressing the importance of consistent descriptors to ensure meaningful, comparable
246 results across monitoring systems.

247 4. **Other AMR monitoring initiatives:** The section highlights important global and regional
248 initiatives, such as the World Health Organization (WHO) integrated global surveillance
249 protocol for ESBL-producing *Escherichia coli* (ESBL-Ec), EU-Wastewater Integrated Surveillance
250 for Public Health (EU-WISH), the European Environment Information and Observation Network
251 (Eionet) working group and the Transatlantic Taskforce on Antimicrobial Resistance (TATFAR).
252 These, alongside the Member State contributions, help to render the picture on the
253 collaborative efforts among countries to standardise AMR monitoring.

254 **5. Conclusion:** Synthesises the information presented in the report, reiterating the importance
255 of standardised approaches and the diverse methodologies employed. It proposes concrete
256 steps for wastewater-based AMR monitoring in Member States and raises additional aspects
257 to consider when undertaking such activities. Overall, it ties together the significance of
258 monitoring AMR, the challenges posed by diverse methods, and the necessity for harmonised
259 protocols.

260

1. Introduction

261

262 Antimicrobial resistance (AMR) is recognised as one of the most pressing global threats to public health
263 and environmental sustainability^{3,4}. Antibiotic-resistant bacteria (ARB) and antibiotic resistance genes
264 (ARGs) circulate across humans, animals, and the environment, undermining the effectiveness of
265 treatments for infectious diseases⁵. Increasing evidence highlights that natural and treated water
266 environment, play a critical role in the emergence, evolution, and dissemination of AMR⁶.

267 Urban wastewater treatment plants (UWWTPs) receive influent from diverse sources, including
268 households, hospitals, industries, and urban runoff. As such, they represent important pathways and
269 reservoirs for ARGs, and in some cases potential hotspots for the amplification and dissemination of
270 resistance determinants into the wider environment. Monitoring AMR in these systems is therefore
271 essential to characterise risks, inform public health and environmental policies, and support targeted
272 interventions aimed at mitigating the spread of resistance.

273 The recast Urban Wastewater Treatment Directive (EU) 2024/3019 (UWWTD) establishes a legal
274 framework for tackling this challenge. Specifically, Article 17(3) mandates the development of a
275 harmonised methodology and minimum sampling frequency for AMR monitoring in urban wastewater,
276 while Article 22 requires Member States to report AMR datasets to the European Commission by 2030
277 and annually thereafter^{7,8}. To support this implementation, the European Commission's Joint Research
278 Centre (JRC) is providing scientific and technical input for the design, evaluation, and validation of AMR
279 monitoring approaches.

280 This report reviews current AMR monitoring practices across EU Member States, drawing on
281 contributions from literature and national initiatives. It examines sampling strategies and analytical
282 techniques applied to detect and quantify ARGs in wastewater, with a focus on culture-based and
283 molecular methods such as quantitative PCR (qPCR), digital droplet PCR (ddPCR), and metagenomics.
284 A key emphasis is placed on the need for harmonised methodologies and metadata collection, to
285 ensure comparability of results across countries and support One Health-aligned surveillance
286 objectives.

³ Naghavi M, Vollset SE, Ikuta KS, Swetschinski LR, Gray AP, Wool EE, et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. *The Lancet*. 2024 Sep 28;404(10459):1199–226.

⁴ Ajulo S, Awosile B. Global antimicrobial resistance and use surveillance system (GLASS 2022): Investigating the relationship between antimicrobial resistance and antimicrobial consumption data across the participating countries. *PLoS One*. 2024;19(2):e0297921.

⁵ CDC. Antimicrobial Resistance. 2025 [cited 2025 Apr 9]. Antimicrobial Resistance Threats in the United States, 2021–2022. Available from: <https://www.cdc.gov/antimicrobial-resistance/data-research/threats/update-2022.html>

⁶ US EPA O. National Priorities Grants: Evaluation of Antimicrobial Resistance in Wastewater and Sewage Sludge Treatment and Its Impact on the Environment [Internet]. 2024 [cited 2025 Jul 22]. Available from: <https://www.epa.gov/research-grants/national-priorities-grants-evaluation-antimicrobial-resistance-wastewater-and>

⁷ Manaia CM. Framework for establishing regulatory guidelines to control antibiotic resistance in treated effluents. *Crit Rev Environ Sci Technol*. 2023 Mar 19;53(6):754–79.

⁸ European Commission. Impact Assessment accompanying the Commission proposal for a recast UWWTD [Internet]. Brussels: European Commission; 2022 Oct [cited 2025 Jul 22]. Report No.: SWD(2022) 541 final. Available from: <https://circabc.europa.eu/ui/group/65764c73-4a57-45dc-8199-473014cf65bf/library/889da570-1fb0-479c-bc7c-3104ad7c8feb/details>

287 By consolidating existing knowledge and practices employed in different EU countries, this report
288 provides the scientific basis for developing standardised AMR monitoring protocols under the recast
289 UWWTD. These efforts will be instrumental in advancing evidence-based policy, fostering international
290 alignment, and ultimately contributing to the containment of AMR in Europe's urban environments.

291

292

293

294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336

2. Methods

On 31 January 2025, an invitation to participate in this review was sent to all EU Member States. National authorities were asked to forward the call to competent organisations within their countries. The request was additionally disseminated via the EU-Joint Action Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI), the EU-WISH Joint Action (JAs), and the Health Security Committee (HSC).

Potential contributors were invited to submit relevant studies and reports on antimicrobial resistance (AMR) monitoring in urban wastewater. The call for contributions remained open until 28 February 2025.

All submitted documents were reviewed with the support of the GPT@JRC tool, which integrates large language models (Llama 3.3 70b instruct and GPT-4o). An ad hoc prompt template (Annex 1) was applied to extract and classify information.

Specifically, the review focused on (i) sampling methods used for wastewater monitoring, (ii) analytical methods applied for AMR/ARG detection, (iii) antibiotic resistance genes (ARGs) and other targets monitored, (iv) descriptors relevant for harmonisation, (v) standardisation efforts reported at national or international level.

In parallel to the Member State submissions, the JRC conducted a desk-based review of standardisation initiatives relevant to AMR monitoring in wastewater. Efforts by international organisations, including the European Committee for Standardisation (CEN), the International Organization for Standardization (ISO), and ASTM International, were considered. The extracted information was systematically collated and analysed. Descriptive statistics and visualisations were produced using the R statistical environment.

It is important to note that the contributions received provide expert insights from Member States on AMR monitoring. While they do not necessarily reflect current national practices, they offer valuable perspectives on the state of the art and contribute to identifying best practices and future directions for implementation.

Furthermore, while the recast UWWTD defines AMR broadly as the ability of microorganisms (bacteria, viruses, fungi, parasites) to survive or grow in the presence of antimicrobial agents (Article 2(22)), the survey responses and received literature from Member States, focused primarily on antibiotic resistance. This emphasis reflects both the state of the scientific evidence and the public health relevance of antibiotics. At present, antibiotic resistance is the most extensively documented component of AMR in wastewater systems, supported by molecular detection methods and standardisation activities at international level. In contrast, systematic monitoring frameworks for antiviral, antifungal, or antiparasitic resistance remain largely undeveloped, with limited data available in the peer-reviewed literature. Consequently, antibiotic resistance serves as a scientifically robust and policy-relevant proxy for AMR in wastewater, while recognising the need for future research to extend monitoring approaches to other microbial classes.

337

3. Findings

338 A total of 109 literature sources, including peer-reviewed papers, country-specific activity reports, and
339 project summaries, were received. Information extracted from the literature contributions shared by
340 each Member State are summarised in Annex 2.


341 **Sampling and analytical methods**

342 The documentation provided by Member States reveals that a variety of sampling and analytical
343 methods are currently applied for AMR monitoring in wastewater. These practices are adapted to the
344 specific objectives of the implementing institutions and reflect both scientific and operational
345 considerations.

346 **Sampling methods.** Composite sampling conducted over a 24-hour period was reported twice as often
347 as grab sampling. In total, 12 Member States reported the use of one or both approaches, with several
348 indicating that composite and grab samples are applied in combination depending on study design and
349 available infrastructure. Composite sampling provides time-averaged information that captures daily
350 variability, whereas grab sampling is more suited to targeted investigations of specific events or
351 localised sources. Some countries, including Austria, Belgium, Sweden, and Portugal, reported more
352 refined composite sampling strategies, applying flow-, time-, or volume-proportional collection.
353 Autosamplers were most frequently reported for composite sampling, improving representativeness,
354 while minimising manual labour and contact with wastewater.

355 **Monitored matrices.** Wastewater was the principal environmental matrix studied for AMR monitoring,
356 with 23 studies explicitly reporting on this source. Several studies included multiple wastewater
357 sources within a single investigation, for instance combining domestic and hospital effluents. Hospital
358 wastewater was analysed in 15 studies, UWWTP influent in 13 studies, and UWWTP effluent in 12
359 studies. In most cases, both influent and effluent were sampled within the same study, allowing
360 assessment of treatment performance as well as temporal and spatial variation in ARG abundance
361 across the wastewater system. Although less frequent, other matrices such as agricultural run-off,
362 farming effluents, and surface waters were also included. Surface water was the third most common
363 matrix overall (n = 13) (Figure 1), reflecting its importance as a receptor environment for UWWTP
364 discharges.

365 **Figure 1.** Number of distinct references citing different water-based environmental matrices



366
367 *Source: EC-JRC.*

368 **Analytical methods.** Culture-based assays were still widely reported, often serving as a first step prior
369 to molecular analysis or sequencing. These were complemented by PCR-based methods, including
370 qPCR, ddPCR, and HT-qPCR, which were highlighted in submissions from Austria, Belgium, Finland,
371 France, Germany, Italy, Netherlands, Portugal, and Sweden. Digital PCR approaches (mainly ddPCR)
372 were reported by Austria, Belgium, Finland, Germany, Italy, and Portugal. Whole-genome sequencing
373 of bacterial isolates following culturing was less common but still present in several references. More
374 advanced approaches included metagenomics, particularly shotgun sequencing, reported by Austria,
375 Belgium, Bulgaria, Finland, the Netherlands, Portugal, and Sweden. Additional methods such as 16S
376 rRNA gene sequencing (for microbial community profiling), metatranscriptomics (focussing on ARG
377 expression), hybrid capture-based sequencing, and standard phenotypic susceptibility testing (e.g.
378 Kirby–Bauer disk diffusion) were also reported, albeit less frequently.

379 Literature shared by Member States does not necessarily document national practices in a systematic
380 way, but rather reflects studies deemed most relevant to this work at the time of the request. The
381 review provides valuable insight into the current landscape of methodologies, but it is not a
382 comprehensive mapping of operational practices across each Member State.

383 ARGs monitored

384 The analysis of submissions by EU Member States identified 109 references reporting on
 385 189 distinct ARG targets across a range of water-based environmental matrices. These matrices
 386 included urban and hospital wastewater, surface waters, soil, and wastewater biofilms.
 387 Of these, 24 ARG targets were specifically monitored in urban wastewater (Table 1; Figure 2).
 388 The widest diversity of ARGs was documented in soils, surface waters, hospital effluents, and biofilms,
 389 emphasising the multiplicity of environmental compartments contributing to ARG occurrence. It is
 390 important to note that the identification of these 189 ARGs was based on single-gene targeted
 391 molecular techniques (e.g., qPCR, ddPCR), reflecting the predominant reliance on such assays in
 392 current monitoring practice. A complete list of all ARGs reported by Member States is provided in
 393 Annex 2.

394 Among them, the 24 most frequently cited ARGs + 1 additional genetic target (*intl1*) in urban
 395 wastewater (Table 1,2) were identified according to the number of references in which they were
 396 reported. While some of these ARGs were also detected in other environmental matrices (such as
 397 surface waters or hospital wastewater), their recurring detection in urban wastewater highlights the
 398 pivotal role of this matrix as both a reservoir and a dissemination pathway for ARGs into the aquatic
 399 environment.

400 **Table 1.** Most frequently cited ARG targets (n. 25) in urban wastewater (ranked by number of citations).

N.	ARG target	# of citations	N.	ARG target	# of citations
1	<i>blaCTX-M</i>	55	13	<i>blaIMP</i>	15
2	<i>blaOXA</i>	51	14	<i>blaSHV</i>	15
3	<i>blaNDM</i>	37	15	<i>sul2</i>	15
4	<i>sul1</i>	35	16	<i>blaCMY</i>	14
5	<i>blaKPC</i>	30	17	<i>qnrS</i>	13
6	<i>blaTEM</i>	29	18	<i>blaGES</i>	12
7	<i>blaVIM</i>	26	19	<i>mecA</i>	12
8	<i>tetA</i>	25	20	<i>cmlA</i>	11
9	<i>vanA</i>	25	21	<i>dfrA</i>	11
10	<i>mcr-1</i>	23	22	<i>tetW</i>	11
11	<i>ermB</i>	22	23	<i>aac(6)-Ib</i>	10
12	<i>tetM</i>	20	24	<i>aadA1</i>	10

401 *Source: EC-JRC*


402 In addition to ARGs, the class 1 integron-integrase gene (*intl1*) was also frequently reported (Table 2).
 403 While not an ARG itself, *intl1* is widely recognised as a proxy for horizontal gene transfer (HGT) and as
 404 an indicator of the potential for ARG mobilization and dissemination ⁹.

405 **Table 2.** Additional genetic target reported and number of citations. *Source: EC-JRC*

N.	Target	# of citations
25	<i>intl1</i> ¹	16

⁹ Ghaly TM, Gillings MR, Penesyan A, Qi Q, Rajabal V, Tetu SG. The Natural History of Integrons. *Microorganisms*. 2021 Nov;9(11):2212.

406 **Figure 2.** Number of distinct ARGs identified across environmental matrices. Visualisation and performed in R
407 (<https://www.R-project.org/>).




408
409 *Source: EC-JRC*

410 Analysis of ARGs across environmental matrices shows that blaCTX-M was the most frequently studied
411 gene in wastewater, followed by blaOXA, blaNDM, sul1, blaKPC, blaTEM, blaVIM, tetA, vanA and mcr-
412 1 (Figure 3).

413
414
415
416

417 **Figure 3.** Heatmap of the 25 most frequently cited ARG targets across environmental matrices. Visualisation
 418 performed in R (<https://www.R-project.org/>).



419
 420 *Source EC-JRC*

421
 422 The *blaCTX-M*, *blaOXA*, *blaNDM*, *blaKPC*, *blaTEM* and *blaVIM* families have received greatest attention
 423 due to their central role in conferring resistance to extended-spectrum beta-lactam (ESBL) antibiotics,
 424 including penicillin, cephalosporins and carbapenemases. These genes were among the most
 425 frequently identified in urban wastewater, highlighting their critical role in antimicrobial resistance
 426 (AMR). The resistance they confer is of highest concern globally:

427
 428 - ESBLs are classified under all priority categories of the WHO List of Medically Important
 429 Antimicrobials (MIA List)¹⁰, the WHO Model List of Essential Medicines (EML List)¹¹, and the WHO
 430 Bacterial Priority Pathogens List 2024 (2024 BPPL)¹².

431 - In the 2024 BPPL, carbapenem-resistant *Acinetobacter baumannii*, carbapenem-resistant
 432 *Enterobacterales* and third-generation cephalosporin-resistant *Enterobacterales* are identified as top
 433 global health threats, due to limited treatment options and few alternative therapies in development.

¹⁰ WHO List of Medically Important Antimicrobials: A risk management tool for mitigating antimicrobial resistance due to non-human use. <https://cdn.who.int/media/docs/default-source/gcp/who-mia-list-2024-lv.pdf>
¹¹ WHO Model List of Essential Medicines – 23rd List, 2023. <https://iris.who.int/bitstream/handle/10665/371090/WHO-MHP-HPS-EML-2023.02-eng.pdf?sequence=1>
¹² WHO Bacterial Priority Pathogens List, 2024: <https://iris.who.int/bitstream/handle/10665/376776/9789240093461-eng.pdf?sequence=1>

434 The *sul1* gene also ranked highly, reflecting both its widespread detection in wastewater and its
435 association with sulfonamide antibiotics, which are poorly removed during wastewater treatment.
436 Importantly, *sul1* is commonly embedded in Class 1 integrons, enabling its persistence and transfer
437 between bacterial species even in the absence of selective pressure.

438
439 - Sulfonamides are classified as “highly important antimicrobials” by the WHO MIA List and fall under
440 the “access” category of the WHO EML List, implying medium resistance risk.
441 Although not listed in the WHO 2024 BPPL, sulfonamides remain widely prescribed and are
442 recommended as first- or second-line treatments [9]. Their monitoring is thus crucial, especially as *sul1*
443 is also highly abundant in hospital wastewater and surface waters, pointing to inputs from both clinical
444 use and veterinary/agricultural sectors. The *vanA* gene was among the top 10 cited ARG targets in
445 wastewater, mainly detected in hospital effluents, agricultural wastewaters, and urban wastewater
446 treatment plants (UWWTPs). *vanA* mediates resistance to glycopeptides (e.g., vancomycin), which are
447 last-resort treatments for severe Gram-positive infections.

448
449 - Glycopeptides are ranked among the antimicrobials with the highest risk for AMR development in
450 the WHO MIA List.

451 - Vancomycin is categorised under “watch” antibiotics in the WHO EML List, reflecting its high
452 resistance selection potential.

453 - The WHO 2024 BPPL highlights the rise of vancomycin-resistant *Enterococcus faecium* (VRE) as a
454 major concern.

455 Given this evidence, *vanA* should be prioritised as a core target in wastewater surveillance to inform
456 antimicrobial stewardship.

457 Tetracycline-resistance genes (*tetA*, *tetM*, *tetW*) also appeared prominently, particularly in surface
458 waters receiving wastewater effluents. While tetracyclines are not prioritised in the WHO 2024 BPPL
459 and show lower resistance potential according to the WHO EML and MIA Lists, monitoring remains
460 relevant within a One Health framework, given their broad dissemination across environmental
461 compartments.

462 The high prevalence of the *ermB* gene highlights the importance of monitoring macrolide resistance.
463 Macrolides are listed as “critically important antimicrobials” in the WHO MIA List.
464 Their clinical importance is reinforced by the inclusion of macrolide-resistant *Streptococcus*
465 *pneumoniae* and macrolide-resistant Group A *Streptococci* as new entries in the 2024 BPPL.

466
467 Other ARGs of particular concern include *mcr-1*, *qnrS* and *mecA* conferring resistance to colistin,
468 quinolones and methicillin-resistant *Staphylococcus aureus* (MRSA), respectively.
469 - Colistin is categorised as a ‘highest priority critically important antimicrobial’ (WHO MIA List).

470 - Quinolones are listed as highly critical in the WHO 2024 BPPL.

471 - MRSA is one of the most prevalent drug-resistant pathogens, particularly in high-income countries.
472 The frequent detection of *mecA* in hospital wastewaters is consistent with this burden.

473
474 Together, these findings underline the public health importance of prioritising ARG monitoring in
475 wastewater environments, both for early-warning surveillance and for guiding the implementation of
476 AMR mitigation strategies under the UWWTD recast.

477 Globally, efforts are underway to harmonise AMR monitoring in order to better characterise its spread
478 and to design effective mitigation strategies. However, the literature reviewed indicates that, although
479 many EU Member States acknowledge the importance of standardised methodologies and the

480 collection of associated metadata, actual practices remain largely heterogeneous and fragmented.
481 Within the EU Member States submissions, the GLASS (WHO Global Antimicrobial Resistance and Use
482 Surveillance System) and One Health frameworks were cited in contributions from Austria, Belgium,
483 and France. An overview of the standardisation efforts reported by individual Member States is
484 provided in Annex 2.

485 Standardisation was found to occur predominantly at the national level, often through the
486 establishment of national monitoring protocols. For example, in France the “AMR-Env” group was
487 established under the French Priority Research Programme on Antimicrobial Resistance, with the
488 objective of developing harmonised approaches for the collection and analysis of samples from natural
489 environments.

490 By contrast, explicit references to international surveillance protocols or guidelines developed by
491 standardisation bodies such as CEN, ISO, or ASTM were largely absent. Two notable exceptions were:
492 1. Finland, which reported active participation in ISO/TC 147/SC 4 (“Microbiological methods”) for
493 international method development;

494 2. France, which indicated compliance with ISO standards for the measurement of micropollutants
495 and ARGs.

496 Additionally, some Member States (Ireland, Italy) reported the adoption of standardised
497 microbiological guidelines from the European Committee on Antimicrobial Susceptibility Testing
498 (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI). Efforts to promote harmonisation
499 of data sharing, methodologies, and nomenclature were also identified. Three Member States
500 reported using specialised databases and software tools to support comparability and interoperability
501 of results. Specifically:

- 502 1. Germany reported use of the NORMAN ARB&ARG database;
- 503 2. Bulgaria reported applying MetaCompare2.0;
- 504 3. Sweden reported use of both the Comprehensive Antibiotic Resistance Database
505 (CARD) and ResFinder.

506 **Descriptors for monitoring ARGs**

507 Urban wastewater is increasingly recognised as a critical conduit for ARGs, providing valuable insights
508 into the prevalence and dissemination of AMR within human and animal populations. To assess and
509 manage AMR risks, Member States have employed a variety of descriptors and monitoring parameters
510 tailored to their national objective. These descriptors are essential for: (i) quantifying the occurrence
511 and dynamics of ARGs in wastewater environments;(ii) facilitating comparability of results across
512 studies and countries; (iii) informing interventions, including intersectoral coordination, regulatory
513 actions (e.g. restrictions on over-the-counter antibiotics), hygiene standards, and public education
514 campaigns.

515 From the survey and literature review, a set of commonly used descriptors could be identified across
516 Member States (Annex 2): Bacterial counts, expressed as CFU per mL of wastewater;

- 517 • Absolute ARG abundance, expressed as gene copies per mL of wastewater;
- 518 • Relative ARG abundance, normalised to 16S rRNA gene copies, per ng DNA, or per
519 mL of total DNA;
- 520 • *int11* gene, included as a marker of horizontal gene transfer (HGT) and ARG mobility;
- 521 • Metadata descriptors, including sampling date, location, analytical methods used,
522 normalisation procedures, and antimicrobial susceptibility thresholds.

523 In addition to these common descriptors, five Member States reported using further parameters to
524 capture more specific aspects of AMR in wastewater:

- 525
- 526 - Austria and Belgium calculated the log reduction of ARG abundance between influent and effluent of
527 wastewater treatment plants (WWTPs) to evaluate treatment efficiency.
- 528 - France measured the abundance of antibiotic residues (ng/L) in wastewater, linking ARG presence
529 with selective pressure from antimicrobial compounds.
- 530 - Bulgaria employed Chao richness estimators to assess bacterial diversity associated with ARG
531 presence.
- 532 - Portugal used fractional quantification, distinguishing ARGs located in bacterial DNA from those
533 carried by phages, thereby assessing ARG transfer potential via bacteriophages.

534

535 These extended descriptors provide complementary perspective: from WWTP performance in ARG
536 reduction to population-level antibiotic consumption, community structure shifts, and the potential
537 for ARG transfer across vectors. When combined with the standardised ARG parameters, they
538 contribute to a more holistic and integrated assessment of AMR dynamics in wastewater
539 environments.

540
541
542

4. Recent AMR monitoring initiatives

543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575

Efforts to monitor antimicrobial resistance (AMR) in the environment have expanded considerably in recent years, driven by the recognition that AMR is a cross-sectoral challenge requiring standardised surveillance and coordinated action. At the global level, international organisations such as the WHO, FAO, and WOAAH have developed frameworks that promote harmonisation of methods, integration of environmental data into One Health monitoring systems, and comparability across countries. These initiatives provide both technical protocols and institutional models that are highly relevant for the implementation of AMR surveillance under the recast Urban Wastewater Treatment Directive (UWWTD). Among them, the WHO’s “Tricycle” and EU-WISH Join Action initiative have gained particular traction as pragmatic global entry points for environmental AMR monitoring.

4.1. “WHO Integrated Global Surveillance on ESBL-producing *E. coli* (Tricycle Protocol)

The WHO Global Tricycle Surveillance protocol ¹³ provides a standardised, trans-sectoral framework for monitoring extended-spectrum beta-lactamase-producing *Escherichia coli* (ESBL-Ec) as an indicator organism for AMR. Developed jointly by the WHO, the Food and Agriculture Organization (FAO), and the World Organisation for Animal Health (WOAH), it is designed to facilitate comparable, affordable, and scalable surveillance across countries, while anchoring AMR monitoring firmly within the One Health approach.

Surveillance Focus:

The protocol targets ESBL-Ec in three priority domains:

- Humans (clinical and community sources),
- The food chain (animals and food products), and
- The environment (urban and animal wastewater, as well as river water).

These domains were selected to represent the major pathways of AMR transmission.

Methodology: The approach relies primarily on culture-based methods, focusing on the detection and quantification of ESBL-Ec in environmental samples, including urban wastewater. Standardised procedures are provided for sample collection, media preparation, and bacterial isolation. While the protocol does not initially require molecular methods (e.g. PCR, WGS), their integration is recommended in subsequent phases for deeper characterisation.

¹³ WHO Global Tricycle Surveillance report: <https://iris.who.int/bitstream/handle/10665/340079/9789240021402-eng.pdf?sequence=1>.

576 **Implementation:** Countries adopting the protocol are encouraged to establish a national coordinating
577 group, typically involving microbiologists, epidemiologists, and national focal points. The WHO
578 provides technical assistance through regional and global offices to support implementation and
579 ensure comparability across sites.

580
581 **Data Management and Analysis:** The protocol promotes the use of *WHONET software* for
582 standardised data management, ensuring consistent collection, storage, and sharing of results.
583 The data are used to assess trends in ESBL-Ec prevalence and to guide targeted AMR interventions.
584

585 **Integration with Other Systems:** The Tricycle protocol is closely linked with the WHO Global
586 Antimicrobial Resistance and Use Surveillance System (GLASS) and with other UN-supported
587 surveillance frameworks, facilitating interoperability and allowing additional “satellite projects”
588 (e.g. molecular studies, environmental expansion) to build on the core design.
589

590 **Challenges and Considerations:** The report highlights challenges related to the complex ecological
591 dynamics of AMR, noting that causal links between sectors cannot always be inferred. It stresses
592 the need for transparency in data interpretation and cautions against the risk of stigmatising
593 specific countries, populations, or sites.
594

595 **Relevance to the recast Urban Wastewater Treatment Directive:**

596 The Tricycle protocol offers several points of synergy with the objectives of the recast UWWTD:

- 597 • It operationalises the One Health mandate by explicitly integrating environmental AMR
598 monitoring with human and animal health sectors.
- 599 • It provides a tested, standardised framework that could inform the development of EU-wide
600 wastewater AMR surveillance methodologies.
- 601 • It offers technical and methodological support, as well as an international platform for data
602 comparability and policy coordination at regional and global scales.

603 **4.2. EU-WISH**

604 The EU-WISH¹⁴ is a 36-month Joint Action under the EU4Health programme (November 2023 – October
605 2026), coordinated by the Statens Serum Institut (SSI, Denmark) with the participation of 62
606 institutions from 26 countries. The initiative is designed to strengthen the EU’s capacity for
607 wastewater-based public health surveillance and to complement national systems by promoting
608 knowledge exchange, best practices, and harmonised approaches. Its scope goes beyond antimicrobial
609 resistance (AMR) to include emerging pathogens, viruses, chemical substances, and other health-
610 related biomarkers. EU-WISH also collaborates with EU-JAMRAI 2¹⁵, reinforcing the environmental
611 component of AMR surveillance within the One Health framework.

¹⁴ EU-WISH - Integrated wastewater monitoring for public health in the EU - [EU-WISH](#)

¹⁵ EU-JAMRAI - [The joint actions EU-WISH and EU-JAMRAI 2 initiate mutual collaboration | EU-JAMRAI](#)

612 **Surveillance Focus:**

613 The project targets a broad range of public health threats, with emphasis on AMR, ESBL-producing
614 *E. coli*, carbapenemase-producing Enterobacteriaceae (CPE), as well as respiratory viruses,
615 polioviruses, non-polio enteroviruses, and selected chemical markers. For AMR, the central goal is
616 to use wastewater as a complementary surveillance system to detect trends in resistance within
617 human populations, thereby enhancing epidemiological intelligence.

618 **Methodology:**

619 The primary analytical methods reported in operative programmes were:

- 620 • *Whole genome sequencing (WGS)* of bacterial isolates cultured from wastewater;
- 621 • *Quantitative PCR (qPCR)* targeting specific ARGs associated with ESBL-Ec and CPE.
622 These approaches allow for both broad genetic characterisation and targeted detection,
623 respectively.

624 **Implementation:**

625 The project was launched in February 2024 in Athens. A mapping survey conducted the same year
626 revealed that 8 of 27 countries (30%) currently operate wastewater AMR surveillance
627 programmes, ranging from exploratory research projects to institutionalised national initiatives.

628 The first capacity-building workshop took place in Lisbon in October 2024, focusing on
629 harmonisation of methodologies and training, with participation also extended to low- and middle-
630 income countries.

631 **Data Management and Use:**

632 The primary objective of these surveillance systems is to provide data on AMR occurrence and
633 trends to inform public health strategies and epidemiological assessments. However, the survey
634 highlighted that integration of wastewater-based AMR data into national decision-making
635 frameworks remains limited. The translation of surveillance results into actionable public health
636 responses is still under development. Furthermore, EU-WISH makes use of the following work
637 packages: (i) “Work Package 5” maps existing national wastewater surveillance systems and
638 stakeholders and develops priority target lists tailored by region and surveillance objectives, (ii)
639 “Work Package 7” focuses on technical harmonisation, including standardised protocols for
640 sampling frequency, analytical workflows, and laboratory methods.

641 **Challenges and Considerations:**

642 The EU-WISH survey identified several key barriers:

- 643 • Lack of integration of wastewater AMR data into established public health surveillance
644 systems;
- 645 • Limited duration of projects and reliance on temporary funding, undermining sustainability;
- 646 • Difficulty in operationalisation, particularly in moving from research findings to applied
647 decision-support tools.

648

649 **Relevance to the UWWTD Recast:**

650 EU-WISH highlights both the potential and the current fragmentation of wastewater-based AMR
651 surveillance in Europe. Its findings emphasise the need for:

- 652 • Stable funding and institutionalisation of AMR wastewater monitoring;
- 653 • Standardised methodologies across Member States;
- 654 • Mechanisms to translate surveillance results into public health action.

655

656

657

658

659 **5. Collaborative Frameworks in Antimicrobial Resistance**
660 **Monitoring:**
661 **The Roles of Eionet and TATFAR**

662 **5.1 European Environment Information and Observation Network (Eionet)**

663 **Surveillance Focus:**

664 The 2025 Eionet pilot study¹⁶ aimed to establish a harmonised framework for monitoring antimicrobial
665 resistance (AMR) in European surface waters and urban wastewater. Conducted across ten self-funded
666 countries, the study focused on rivers downstream of urban wastewater treatment plants (WWTPs).
667 The primary objective was to develop methodologies for collecting and reporting AMR data,
668 supporting revisions of EU water directives.

669 **Methodology:**

670 The pilot study employed a dual approach combining culture-based techniques and quantitative PCR
671 (qPCR) analyses. A strategically selected panel of six core antimicrobial resistance genes (ARGs) was
672 targeted:

- 673 • *16S rRNA*
- 674 • *intI1*
- 675 • *aadA1*
- 676 • *ermB*
- 677 • *blaCTX-M1*
- 678 • *vanA*

679 Additionally, three optional genes were included:

- 680 • *tetW*
- 681 • *sul1*
- 682 • *blaKPC*

683 Sampling focused on rivers downstream of urban WWTPs, and the study applied the *WHO Tricycle*
684 *protocol*.

685 **Implementation:**

686 Participating countries implemented the harmonised framework at representative WWTP sites and
687 surface water locations. Challenges encountered included funding limitations, varied national

¹⁶ [Pilot study on antimicrobial resistance monitoring in European surface waters - Final report of the Eionet Working Group](#)

688 capacities, and differing technical expertise among Member States. Despite these challenges, the pilot
689 study was viewed as a successful step toward EU-wide AMR monitoring.

690 **Key Findings:**

- 691 • *Spatial Gradients:* Clear spatial gradients in ARG abundance were observed, reflecting
692 variations in human impact across sites.
- 693 • *Gene Removal Efficiency:* Wastewater treatment effectively reduced both E. coli and ESBL-
694 producing E. coli (ESBL-Ec) by over 99%.
- 695 • *Methodological Variability:* Significant differences in laboratory practices and technical
696 capabilities were detected, highlighting the need for harmonisation.
- 697 • *Data Integration Potential:* The pilot demonstrated the feasibility of combining culture-based
698 and molecular methods to provide a robust, multi-dimensional picture of AMR in wastewater
699 and surface waters.
- 700 • *Recommendations:* Establishing standardised protocols and quality assurance/control
701 frameworks is critical for generating reliable, comparable data to support policy and public
702 health action at the EU scale.

703 **Sampling Considerations:**

- 704 • *Sampling Protocols:* The study employed the WHO Tricycle protocol for culturing due to the
705 absence of standardized EU methods for water.
- 706 • *Sampling Locations:* Sampling focused on rivers downstream of urban WWTPs, providing
707 insights into the impact of effluent on surface water quality.
- 708 • *Sampling Frequency:* The study involved sampling at multiple sites over a period, though
709 specific details on the frequency and duration of sampling were not provided in the available
710 sources⁷.

711 **Data Management and Reporting:**

- 712 • *Data Reporting Template:* A custom data reporting template aligned with the [European](#)
713 [Environment Agency's WISE-6 model](#) was developed, facilitating standardized data
714 submission across participating countries .
- 715 • *Data Harmonization:* The study aimed to harmonise methodologies for sampling, analysis,
716 and reporting, supporting revisions of EU water directives.
- 717 • *Quality Assurance:* The study highlighted the need for rigorous quality assurance and control
718 (QA/QC) measures to ensure data comparability and reliability on a Europe-wide scale.

719 **Cost Considerations:**

- 720 • *Method Selection:* Quantitative PCR (qPCR) was used as the main method for its cost-
721 effectiveness, enabling the detection of key antimicrobial resistance genes (ARGs) across
722 multiple sites.
- 723 • *Funding Challenges:* The pilot study faced challenges including funding limitations, varied
724 national capacities, and differing technical expertise among participating countries.

- 725 • *Resource Allocation:* Despite these challenges, the study was viewed as a successful step
726 toward EU-wide AMR monitoring, indicating that with appropriate resource allocation, such
727 initiatives can be effective.

728 **5.2 The Transatlantic Taskforce on Antimicrobial Resistance (TATFAR)**

729 **Surveillance Focus:**

730 Established in 2009 and expanded over time to include the EU, U.S., Canada, Norway, and the UK,
731 TATFAR ¹⁷ adopts a One Health perspective for AMR surveillance, explicitly acknowledging the
732 importance of environmental vectors—including water systems—as integral to the AMR ecosystem.

733

734 **Methodology & Harmonisation Efforts:**

735 Although TATFAR does not prescribe standardised monitoring protocols for AMR in water, it actively
736 facilitates harmonisation through knowledge exchange.

737 The Taskforce:

- 738 • Shares methodologies including culture-based detection, qPCR, and genomic approaches.
- 739 • Emphasises the development and alignment of QA/QC standards, target gene panels (e.g. ESBL
740 and carbapenemase genes), and normalisation practices in sampling (essential measures for
741 transatlantic data comparability).

742 **Implementation and Collaborative Mechanisms:**

743

744 TATFAR’s structure is designed to foster ongoing coordination:

- 745 • It issues progress reports and jointly developed resources, such as those on antibiotic use
746 metrics, stewardship strategies, and surveillance frameworks.
- 747 • It hosts periodic meetings and workshops, including a significant virtual conference in
748 September 2021 that convened partners from all member regions (EU, U.S., Canada, Norway,
749 UK) alongside WHO and other stakeholders. The meeting set the stage for its 2021–2026
750 implementation plan [Public Health](#).

751 **Data Management & Sharing:**

752 While TATFAR doesn’t operate its own data platform, it promotes data interoperability across
753 jurisdictions by aligning surveillance priorities, collaborating on surveillance tool development, and
754 reinforcing frameworks for sharing methodologies and outcomes.

755 **Challenges & Strategic Directions:**

756 TATFAR’s [recent progress reports](#) highlights future priorities, including:

- 757 • Advancing wastewater surveillance for environmental AMR.
- 758 • Enhancing cross-sector collaboration on stewardship, diagnostics, and AMR transmission
759 routes.

¹⁷ [Transatlantic Task Force on Antimicrobial Resistance | HHS.gov](#)

760 • Addressing methodological gaps in data comparability and expanding surveillance coverage.

761 **Relevance to the recast UWWTD**

762 TATFAR's role offers valuable insights for the recast UWWTD including:

763 • It demonstrates how inter-jurisdictional collaboration can align surveillance approaches
764 across differing regulatory frameworks.

765 • The emphasis on fostering harmonised methodologies, QA/QC practices, and target gene
766 panels informs the development of EU-wide standardisation.

767 • TATFAR's strategic positioning can support **the EU directive's ambition** to integrate
768 wastewater surveillance within One Health frameworks, enabling comparative data and
769 collective response strategies at a transatlantic level.

770

771

772

773

6. International standardisation

774 International standardisation for monitoring AMR is in place, with several organisations involved
775 and development underway to improve harmonisation for wastewater and other sectors including
776 water and food, and (13). Currently in place are:

777

778 **ISO (International Organization for Standardization):** ISO develops international standards through
779 technical committees and consensus among member bodies, emphasising harmonised methods based
780 on collective agreement and formal balloting. Regarding antimicrobial resistance (AMR), several
781 standards relevant to healthcare organization management and laboratory quality assurance are
782 currently in draft or committee stages.

783 Dedicated ISO standards specifically targeting AMR monitoring in wastewater and other water sources
784 are still in the early phases of development. For instance, work is ongoing within relevant technical
785 committees, with draft standards expected to advance through the committee stages over the next 1-
786 3 years. However, precise delivery dates have not yet been published.

787

788 In the meantime, existing ISO protocols provide foundational guidance for pathogen detection and
789 antimicrobial susceptibility testing. These include [ISO 19458](#), which covers microbiological sampling of
790 water; [ISO 11731](#), focused on Legionella detection; and [ISO 20776-1](#) and [20776-2](#), which define
791 antimicrobial susceptibility testing methods originally designed for clinical isolates but widely adapted
792 for environmental bacterial characterisation. These established protocols serve as valuable interim
793 references while dedicated AMR surveillance standards continue to be developed.

794 **CEN (European Committee for Standardization):** CEN develops regionally tailored standards that align
795 with European regulatory priorities and environmental health needs, often complementing ISO
796 methods. CEN is actively engaged in developing and updating standards supporting wastewater
797 treatment and water monitoring, including aspects crucial for antimicrobial resistance (AMR)
798 surveillance¹⁸.

799 Key standards include EN ISO 19458 (Water quality: Sampling for microbiological analysis), EN ISO
800 9308-1/2 (Coliform enumeration), EN 12566, ISO 20776 (Parts 1 and 2), and various standards under
801 the technical committee CEN/TC 230. Together, these provide a comprehensive framework for
802 chemical and microbiological water quality monitoring, forming a strong basis for AMR surveillance
803 initiatives¹⁹.

804 Currently, several AMR-related CEN standards are under development or review, aligned with broader
805 European strategies to mitigate AMR risks in the environment. Although precise delivery dates are not
806 yet publicly available, ongoing work supports enhanced environmental surveillance capacities,
807 especially focusing on wastewater treatment plants and surface waters²⁰.

808 This progress is closely coordinated with European One Health AMR action plans and associated
809 research partnerships promoting standardised surveillance methods. In particular, the European Joint
810 Programming Initiative on AMR (JPIAMR) has advanced harmonised molecular and culture-based

¹⁸ <https://pmc.ncbi.nlm.nih.gov/articles/PMC9261269/>

¹⁹ [Update on AMR-related issues in several environmental policy contexts](#)

²⁰ [Call-to-Action-of-the-European-Network-on-Infection-Prevention-and-Antimicrobial-Resistance-ENIPAR.pdf](#)

811 surveillance techniques relevant to wastewater-based AMR monitoring. Key outputs informing this
812 work include the development of transnational research agendas, inter-laboratory studies, and
813 methodological guidelines. Specific projects include: (i) RESERVOIR, (ii) BALTIC-AMR, (iii) DECODE, and
814 (iv) OASIS. Together, these initiatives support the harmonisation efforts presented in this report ^{21,22,}

815 **ASTM International:** ASTM International develops standards for a wide range of industries including
816 environmental testing. Certain ASTM standards, such as ASTM D5465, are commonly used in
817 conjunction with ISO and CEN methods for detecting indicators like *coliforms* and *E. coli* in water.
818 However, specific ASTM methods explicitly focused on antimicrobial resistance (AMR) detection in
819 water are still under development and delivery timelines remain to be announced.²³
820 These developments aim to complement existing international standards and address gaps in
821 environmental AMR surveillance.²⁴

822 **National and regional** for antimicrobial resistance (AMR) monitoring in water are used variably across
823 countries. For example, in Germany, the DIN 38411 standard series—including methods for
824 microbiological examination of water, wastewater, and sludge—is commonly applied for bacterial
825 indicator analysis and AMR-related monitoring ²⁵. These methods include both culture-based
826 techniques and modern identification approaches, ensuring comprehensive surveillance of microbial
827 communities and resistance traits.

828
829 In the United States, AMR monitoring in water typically employs a combination of culture-based
830 assays, quantitative PCR (qPCR), and metagenomic sequencing. National regulatory and public health
831 agencies, such as the Environmental Protection Agency (EPA) ²⁶ and the Centers for Disease Control
832 and Prevention (CDC)²⁷, provide various protocols which guide these assessments. However, these
833 protocols are diverse and sometimes lack full harmonisation for inter-laboratory comparability.
834 Ongoing national efforts in the US focus on developing standardised frameworks to ensure consistent
835 and comparable AMR surveillance data across institutions. These frameworks integrate molecular and
836 culture-based methods to address current gaps and improve environmental AMR monitoring
837 comprehensiveness. While precise timelines for the completion and delivery of these frameworks are
838 not yet publicly disclosed, stakeholder collaborations suggest active development stages with
839 expected advancements in the near future. The Joint Research Centre (JRC) involvement with the
840 Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) aims to facilitate more detailed
841 information exchange and alignment of standards between Europe and the US, potentially enhancing
842 cross-border cooperation and technical harmonisation.

²¹ [How to establish a hospital wastewater surveillance program for antimicrobial resistance: Current experience and future knowledge gaps](#)

²² [Measuring water pollution effects on antimicrobial resistance through explainable artificial intelligence - ScienceDirect](#)

²³ [A one health approach for monitoring antimicrobial resistance: developing a national freshwater pilot effort - PMC](#)

²⁴ [A one health approach for monitoring antimicrobial resistance: developing a national freshwater pilot effort - PMC](#)

²⁵ DIN Standards Series - [Results](#)

²⁶ [linking_epa_to_a_one_health_focused_national_scale_monitoring_of_antimicrobial_resistance.pdf](#)

²⁷ [Strengthening Surveillance - Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine - NCBI Bookshelf](#)

843
844

7. National Obligations for AMR Monitoring in Aquatic Systems: EU-27 Comparative Analysis

845 There is currently no explicit EU regulatory requirement for monitoring or controlling antibiotic
846 residues or antimicrobial resistance genes (ARGs) in aquatic environments. However, this gap is
847 acknowledged, and the topic is under active discussion, with ongoing efforts to develop
848 recommendations for action²⁸. The EU Water Framework Directive (WFD)²⁹ provides a mechanism for
849 setting Environmental Quality Standards (EQS) for water pollutants, but AMR selection risk and
850 antibiotic residues are not currently included among binding EQS. The WFD does allow Member States
851 to designate additional river basin-specific pollutants and establish corresponding national EQS
852 adapted to local conditions. Ongoing review processes aim to assess the need for including AMR-
853 related indicators and antibiotic residues within future EQS frameworks.

854 The analysis of national obligations is based on a structured review of Member States' legislation,
855 policy instruments, and institutional mandates relevant to AMR monitoring in aquatic environment,
856 including in wastewater. This work has identified whether binding national obligations exist, and
857 highlights relevant national plans and instruments, EU linkages, and scientific references. Data were
858 collected through desk research of national legal databases and government portals, scientific
859 literature analysis, review of national-level directives, OECD and ECDC reports, consultation of the
860 WHO TrACSS Global Database³⁰ and results from the 2024 WHO Tracking Antimicrobial Resistance
861 Country Self-Assessment Survey³¹. Table A2 in Annex 3 collects these findings. The dataset may not
862 reflect all ongoing initiatives due to variability in national reporting and evolving legislation.

863 Key results include:

864 (i) With regard to urban wastewater, no EU Member State has yet established binding national
865 regulations that explicitly mandate routine AMR monitoring at wastewater treatment plants; (ii)
866 Sweden is currently the only EU Member State with a binding legal requirement for AMR-related
867 monitoring in surface waters, implemented through Environmental Quality Standards (EQS). For
868 example, ciprofloxacin is regulated with a Maximum Allowable Concentration EQS (MAC-EQS) of 0.1
869 µg/L. (iii) All other Member States currently rely on voluntary, research-driven, or pilot-based
870 initiatives for urban wastewater AMR monitoring, but also include aspects of surface water
871 surveillance and broader water contamination control under the One Health approach.
872 (iv) EU-level coordination is reflected in Member State participation in initiatives such as JPIAMR³²,
873 EU-JAMRAI³³, EARS-Net³⁴, and alignment with the EU AMR Action Plan and WHO Global Action Plan
874 on AMR; (v) the European Commission and environmental agencies recognise the health risk posed by
875 environmental AMR and recommend establishing methods and standards for risk-based regulation of
876 antimicrobial residues in water.

²⁸ European Environment Agency (EEA) report [Water signals — European Environment Agency](#)

²⁹ Water Framework Directive - [Water Framework Directive - European Commission](#)

³⁰ [Global Database for Tracking Antimicrobial Resistance \(AMR\) Country Self-Assessment Survey \(TrACSS\)](#)

³¹ [Results from the 2024 Tracking Antimicrobial Resistance Country Self-Assessment Survey \(TrACSS\)](#)

³² EU AMR projects [JPIAMR](#), [OHAMR](#)

³³ EU AMR project [EU-JAMRAI](#)

³⁴ [European Antimicrobial Resistance Surveillance Network \(EARS-Net\)](#)

8. Analytical methods for monitoring AMR in water: strengths and limitations

877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922

In the absence of harmonised international standards, a diverse suite of analytical methodologies is currently employed for antimicrobial resistance (AMR) monitoring in water environments. These methodologies span traditional culture-based assays to cutting-edge molecular and genomic approaches, each characterised by unique advantages and constraints regarding sensitivity, breadth of detection, interpretability, and operational feasibility for regulatory or research use.

Culture-based methods

Culture-based methods remain foundational for detecting viable antimicrobial-resistant bacteria (ARB) and generating quantitative phenotypic resistance profiles. Standardised protocols such as coliform enumeration (e.g., EN ISO 9308) and the World Health Organization's (WHO) Tricycle protocol (22), endorsed by the European Environment Information and Observation Network (Eionet), facilitate targeted detection of priority bacterial species and resistant phenotypes (e.g., ESBL-producing *E. coli*). These approaches afford direct evidence of viable, culturable resistance reservoirs and allow antimicrobial susceptibility testing critical for clinical and epidemiological contexts. Nonetheless, they are limited by lengthy incubation requirements, labour intensity, and an inability to capture viable but non-culturable (VBNC) bacteria and fastidious or slow-growing taxa prevalent in complex aquatic microbiomes, potentially underestimating resistance diversity and abundance in environmental matrices.

Molecular approaches

Molecular methods, especially quantitative polymerase chain reaction (qPCR), have rapidly gained prominence due to their high sensitivity, specificity, and rapid turnaround in detecting known antibiotic resistance genes (ARGs). qPCR facilitates high-throughput monitoring across large sample sets, independent of bacterial viability, making it suitable for broad environmental surveillance. European pilot studies (like Eionet) have demonstrated feasibility for harmonised qPCR protocols incorporating standardised primer-probe sets, thermocycling conditions, and synthetic calibration standards (e.g., gBlocks), which improve inter-laboratory comparability and data robustness. However, qPCR's reliance on prior knowledge of target ARG sequences restricts detection of emerging or novel resistance mechanisms, and molecular detection does not inherently confirm phenotypic resistance expression. The development of certified reference materials, such as those currently underway at the JRC, will further enhance quality assurance and method standardisation.

High-resolution genomic techniques, comprising whole genome sequencing (WGS) and shotgun metagenomics, offer transformative potential for characterising the entire resistome, mobile genetic elements, and microbial community structure in water environments. These comprehensive approaches enable discovery of novel ARGs, facilitate strain-level source tracking, elucidate gene mobility, and support refined risk assessment models within integrated One Health frameworks. Recent reviews and ongoing monitoring programs emphasise WGS and metagenomics as critical to unravelling AMR dynamics across environmental compartments. Nevertheless, their widespread adoption is hindered by high financial and computational costs, the necessity for specialised bioinformatics expertise, extended data processing times, and the current absence of internationally accepted standardised analytical pipelines and quality control measures.

923

924 Emerging or complementary technologies: Matrix-assisted laser desorption/ionisation time-of-flight
925 (MALDI-TOF) mass spectrometry, while widely used in clinical microbiology for microbial identification
926 and resistance profiling, remains underexplored in environmental contexts due to instrumentation
927 costs and the need for protocols tailored to water matrices. Lab-on-a-chip and microfluidic platforms
928 represent innovative tools for on-site AMR detection by integrating molecular assays into portable,
929 miniaturised systems. These technologies could enable near real-time monitoring at wastewater
930 treatment plants or environmental hotspots, although most remain in early developmental stages and
931 require thorough validation for consistent performance across diverse environmental conditions.
932 Similarly, pilot systems such as smart-chip Resistomap platforms offer potential for multiplexed
933 resistance profiling, though they also require further technical refinement before they can be
934 implemented widely.

935

936 Overall, the current landscape of AMR monitoring in wastewater benefits from a complementary
937 toolbox integrating culture-based methods, targeted molecular assays, and broad genomic
938 approaches. Future efforts should prioritise international harmonisation of protocols, validation and
939 certification of reference materials, and the strategic integration of emerging technologies. Such
940 coordinated strategies are essential to enhance sensitivity, specificity, and scalability of environmental
941 AMR surveillance. Additionally, incorporating comprehensive One Health perspectives entails
942 expanding ARG monitoring to encompass resistance determinants beyond traditional antibiotic
943 targets, including those linked to antifungals, antivirals, and antiparasitic agents, as well as
944 underexplored microbial groups such as fungi, viruses, and protozoa.

945

9. Discussion

946 In response to the requirements of the Article 17(3) of the recast UWWTD the JRC has undertaken a
947 comprehensive scientific effort to support the development of a harmonised methodology and
948 certified reference material for monitoring antimicrobial resistance (AMR) in urban wastewater,
949 providing a crucial contribution to the effective implementation of the Directive. Anchored in the One
950 Health framework, this work directly contributes to the European Union’s broader objectives on public
951 health surveillance and environmental protection.

952 This report aims to provide the technical foundation for consistent and comparable AMR surveillance
953 across EU Member States, ahead of the 2030 reporting obligations. Through scientific literature
954 analysis, active stakeholder consultation, and providing technical support for the implementing act,
955 the JRC has delivered key recommendations to facilitate the implementation of AMR monitoring in
956 urban wastewater, laying the groundwork for effective regulatory action and long-term health risk
957 mitigation.

958
959 Although AMR surveillance has traditionally focused on human and animal health, increasing evidence
960 highlights the natural environment as a critical reservoir and potential driver of AMR emergence and
961 dissemination³⁵. Consistent with the One Health approach, systematic environmental monitoring,
962 particularly of antimicrobial residues and resistance determinants in urban wastewater, is
963 indispensable to elucidate the role of environmental contamination in AMR proliferation, promote
964 prudent antimicrobial use, inform effective infection prevention strategies and assess associated risks
965 to human health.

966 To effectively confront this challenge, it is essential to identify critical control points, establish reliable
967 surveillance frameworks, and deploy technological solutions aimed at preventing environmental
968 contamination by antibiotic-resistant bacteria and bacterial ARGs.

969 In this regard, monitoring both the influent and effluent of WWTPs can provide critical insight into
970 AMR inputs from the community and, the effectiveness of treatment processes in reducing resistance
971 loads before environmental discharge.

972
973 Analysis of scientific literature and Member States’ initiatives reveals substantial heterogeneity in AMR
974 monitoring methodologies within urban wastewater contexts. Variations exist in sampling strategies
975 (composite vs. grab samples), normalisation procedures (accounting for flow, volume, or temporal
976 factors), and monitored matrices, reflecting divergent national contexts and objectives. Wastewater
977 influent and effluent from treatment plants consistently emerge as primary matrices due to their
978 critical role in reflecting AMR reservoirs and treatment efficacy.

979 Culture-based methods remain valuable for isolating viable bacteria and conducting population-level
980 analyses. However, their limitations in standardisation, scalability, and time-efficiency restrict their
981 broader application. In contrast, qPCR offers a faster turnaround, greater reproducibility, and targeted
982 approach for quantifying defined ARGs. It is particularly well-suited to wastewater environments,

³⁵ <https://www.frontiersin.org/articles/10.3389/fmicb.2021.766242/full>

983 where bacteria may be viable but non-culturable, and where rapid detection of resistance markers is
 984 essential.

985 Findings from the Eionet pilot study also support the feasibility of deploying standardised qPCR
 986 methods in a harmonised European monitoring framework. This includes consensus development
 987 around primer-probe sets, thermocycling protocols, and the use of synthetic standards (e.g., gBlocks)
 988 for calibration and inter-laboratory comparability. These efforts can be further strengthened through
 989 certified reference materials, e.g., the one currently being developed by the JRC, which will strengthen
 990 quality assurance and intercalibration efforts.

991
 992 Across Europe, Member States reported a total of 189 ARG targets identified in environmental
 993 matrices, emphasising the complexity and scale of AMR in wastewater systems. Drawing on this
 994 extensive dataset and applying a prioritisation framework that considers both public health relevance
 995 (WHO 2024 BPPL) and environmental significance (as identified by the Eionet AMR Working Group
 996 pilot study on AMR monitoring in surface waters), the JRC has selected 24 ARG targets for qPCR-based
 997 AMR monitoring in urban wastewater plus 1 additional genetic target (*intl1*) in urban wastewater.
 998 From this selection, a further selection resulted in 12 key ARGs (Table 3): *blaCTX-M*, *blaOXA*, *mcr-1*,
 999 *blaKPC*, *vanA*, *ermB*, *mecA*, *qnrS*, *aadA1*, *sul1*, *tetA*, and *dfrA*. The selection reflects a representation of
 1000 one to three ARGs per major antibiotic class, including beta-lactams (*blaCTX-M*, *blaOXA*, *blaKPC*),
 1001 colistin (*mcr-1*), glycopeptides (*vanA*), macrolides (*ermB*), quinolones (*qnrS*), streptomycin (*aadA1*),
 1002 MRSA (*mecA*) tetracyclines (*tetA*), sulfamethoxazole (*sul1*) and trimethoprim (*dfrA*).

1003 Among these, particular attention is now being directed towards four high-priority ARGs: *blaCTX-M*,
 1004 *sul1*, *blaKPC*, and *ermB*, which are considered especially relevant under the One Health framework, as
 1005 they are also recognised as priority targets by both the WHO 2024 BPPL and the Eionet AMR Working
 1006 Group (Table 2).

1007 **Table 2.** Priority ARG targets proposed for environmental monitoring under the One Health framework. This
 1008 selection reflects ARGs of high relevance to both public health and environmental dimensions, based on
 1009 alignment with WHO priority pathogens and Eionet AMR Working Group recommendations. The table highlights
 1010 four key targets: *blaCTX-M*, *blaKPC*, *sul1*, and *ermB*, for harmonised qPCR-based surveillance in urban wastewater
 1011 systems across Europe.

Relevance	#	ARG target	Antibiotic	# of citations	WHO 2024 BPPL	Eionet AMR working group
One Health	1	<i>blaCTX-M</i>	beta-lactams	55	Yes	Yes
	2	<i>sul1</i>	sulfamethoxazole	35	Yes	Yes
	3	<i>blaKPC</i>	beta-lactams	30	Yes	Yes
	4	<i>ermB</i>	macrolides	22	Yes	Yes

1012
 1013 *Source: EC-JRC*

1014
 1015 Building on these insights, this report recommends the implementation of a qPCR-based AMR
 1016 surveillance strategy. The JRC is currently working with its partners to validate a suitable qPCR-method
 1017 on the reported targets.

1018 Ensuring data quality and comparability, clear guidance on analytical validation (e.g., qPCR efficiency
 1019 thresholds) is necessary, alongside interlaboratory proficiency testing and the use of reference
 1020 materials. The routine reporting of qPCR results, including Ct values or gene copies per millilitre

1021 (gene/mL), should adhere to simplified, standardised formats similar to those used for traditional
1022 chemical concentration reporting.

1023 Equally important is the facilitation of data sharing. International platforms such as the WHO GLASS
1024 and the EU's Super-Site Sentinel System operated by JRC, HERA and HaDEA, are pivotal in facilitating
1025 data exchange, collaborative monitoring, and dissemination of best practices across countries.
1026 Moreover, capacity-building initiatives are critical to strengthen expertise, particularly in countries
1027 with less experience in environmental and wastewater AMR monitoring.

1028 Furthermore, metagenomics has strategic potential in environmental AMR monitoring and warrants
1029 targeted pilot studies and research investments. At present high costs, technical complexity, and data-
1030 intensive requirements are currently limiting the widespread application of metagenomics. Voluntary
1031 exploration of metagenomic approaches, alongside other emerging technologies such as lab-on-a-chip
1032 platforms, within national surveillance programmes is strongly encouraged where resources and
1033 technical capacity permit. These efforts are further supported by initiatives such as the JRC's offer of
1034 technical assistance at no additional cost as part of the newly established EU Sentinel System,
1035 facilitating broader capacity-building and innovation uptake. This includes methodological guidance,
1036 access to reference materials, databases, and training opportunities. Such support facilitates broader
1037 innovation uptake, accelerates harmonisation of approaches, and reduces the risk that resource-
1038 limited countries are excluded from next-generation surveillance developments.

1039 Such exploratory work can inform the refinement of future monitoring frameworks, help uncover
1040 novel resistance pathways and broaden the scope of surveillance to include underrepresented
1041 microbial domains such as fungi, viruses, and protozoa, thus contributing to a more comprehensive
1042 and integrated One Health approach. Sustained and coordinated engagement among EU Member
1043 States remains the *conditio sine qua non* for the effective and harmonised advancement of
1044 environmental AMR surveillance.

1045 **9.1. Preliminary method proposal for AMR monitoring in urban wastewater**

1046 Building on the evidence acquired through the reviewed literature, this report proposes a targeted,
 1047 cultivation-free qPCR monitoring approach for AMR monitoring in wastewater. qPCR offers precise
 1048 quantification of known ARGs of concern and has already been undertaken in AMR monitoring in large
 1049 part of EU Member States. This preparatory support reduces entry barriers and facilitates a smoother
 1050 uptake of harmonised monitoring practices once the implementing acts under the Urban Wastewater
 1051 Treatment Directive enter into force.

1052 A list of 25 targets has been curated based on the submitted Member States’ literature, in conjunction
 1053 with expert opinion, internal discussions and existing international lists (Table 3).

1054 **Table 3.** Priority antimicrobial resistance gene (ARG) targets proposed for harmonized AMR monitoring within
 1055 the One Health framework. ARGs are grouped into four relevance categories—One Health, Environmental, Public
 1056 Health, and Scientific—based on their alignment with the WHO 2024 Bacterial Priority Pathogens List (BPPL), the
 1057 Eionet AMR Working Group pilot study on European surface waters, and their citation frequency in the literature.
 1058 This categorization highlights ARGs of cross-sectoral importance for consistent qPCR-based surveillance in urban
 1059 wastewater and related environmental compartments. ¹ *int11* is not considered an ARG but is often included due
 1060 to its association with the spread of antibiotic resistance genes. It is used also as an indicator for horizontal gene
 1061 transfer (HGT) and transmission of ARGs.

Relevance	#	ARG target	Antibiotic	# of citations	WHO 2024 BPPL	Eionet AMR working group
One Health	1	<i>blaCTX-M</i>	beta-lactams	55	Yes	Yes
	2	<i>sul1</i>	sulfamethoxazole	35	Yes	Yes
	3	<i>blaKPC</i>	beta-lactams	30	Yes	Yes
	4	<i>ermB</i>	macrolides	22	Yes	Yes
Environmental	5	<i>vanA</i>	glycopeptides	25	No	Yes
	6	<i>int11</i> ¹	-	16	No	Yes
	7	<i>tetW</i>	tetracycline	11	No	Yes
	8	<i>aadA1</i>	streptomycin	10	No	Yes
Public Health	9	<i>qnrS</i>	quinolones	13	Yes	No
	10	<i>mecA</i>	MRSA	12	Yes	No
	11	<i>blaOXA</i>	beta-lactams	51	Yes	No
	12	<i>blaNDM</i>	beta-lactams	37	Yes	No
	13	<i>blaTEM</i>	beta-lactams	29	Yes	No
	14	<i>blaVIM</i>	beta-lactams	26	Yes	No
	15	<i>blaIMP</i>	beta-lactams	15	Yes	No
	16	<i>blaSHV</i>	beta-lactams	15	Yes	No
	17	<i>blaCMY</i>	beta-lactams	14	Yes	No
	18	<i>aac(6')-Ib</i>	quinolones	10	Yes	No
19	<i>ermF</i>	macrolides	10	Yes	No	
Scientific	20	<i>tetA</i>	tetracycline	25	No	No
	21	<i>mcr-1</i>	colistin	23	No	No
	22	<i>tetM</i>	tetracycline	20	No	No
	23	<i>blaGES</i>	beta-lactams	12	No	No
	24	<i>dfrA</i>	trimethoprim	11	No	No
	25	<i>sul2</i>	sulfamethoxazole	15	No	No

1062 Source: EC-JRC

1063 The first four targets listed in Table 3 are considered of highest priority and represents the minimum
1064 for AMR monitoring in wastewaters

1065 Targets were selected as a result of their One Health impact, highlighted both by the WHO 2024 BPPL
1066 and the Eionet AMR working group report on AMR monitoring in European surface waters (also see
1067 Table 2 above). As the environment can act both a reservoir and transmission pathway for AMR,
1068 environmentally relevant ARGs were lifted as the second group of priority targets; these targets align
1069 with the Eionet working group study. ARG targets of public health importance were selected in light of
1070 the WHO 2024 BPPL. Finally, to complete the list, five scientifically relevant targets, identified through
1071 our revision process and internal discussions, were included. The list includes also *intl1*, which is not
1072 considered an ARG, but is an important environmental marker associated with AMR.

1073 ***Frequency of monitoring***

1074 Based on scientific evidence and expert consensus, we recommend monthly qPCR monitoring for both
1075 influent and effluent at each urban wastewater treatment plant (UWWTP), resulting in 24 samples per
1076 year. This frequency is considered sufficient to capture temporal trends in ARG abundance while
1077 remaining feasible in terms of cost and operational resources.

1078 **Scientific rationale:**

- 1079 - Temporal resolution: Monthly sampling captures seasonal variations, short-term fluctuations, and
1080 potential episodic spikes in ARGs, which are critical for detecting trends, emerging resistance, or
1081 public health risks.
- 1082 - Statistical robustness: Regular sampling provides enough data points to perform meaningful trend
1083 analyses and correlation with environmental and epidemiological variables, reducing the risk of
1084 misleading conclusions due to outliers.

1085 The proposed cultivation-free qPCR monitoring has been reviewed by experts and is recommended for
1086 its ability to rapidly, sensitively, and reproducibly detect ARGs directly from wastewater DNA. This
1087 approach supports routine surveillance while avoiding the higher labor and time demands of culture-
1088 based methods, effectively balancing data quality, resource allocation, and temporal variability. Here,
1089 data quality refers to the reliability, representativeness, and reproducibility of measurements, ensured
1090 through standardized sampling, consistent processing, and validated qPCR assays.

1091 More frequent monitoring can provide a detailed understanding of antimicrobial use levels and
1092 evolution of AMR genes, but it also requires more resources. Furthermore, the frequency of
1093 wastewater monitoring can vary depending on regulatory requirements, the specific goals of the
1094 monitoring programme, and the logistical and financial resources available. In this light, frequency of
1095 routine monitoring of selected AMR targets may require adjustments in the case of specific events
1096 (e.g., seasonal changes, industrial discharges, or public health emergencies), study-related
1097 assessments or introduction of regulatory frameworks which dictate specific requirements for AMR
1098 monitoring. Therefore, monitoring activities initiated by Member States should be adapted to align
1099 with minimum requirements, their scientific objectives and practical considerations.

1100 **Metagenomic sequencing**

1101 Within the proposed AMR monitoring strategy, metagenomic sequencing will function as a
1102 complementary tool, carried out by Member States on a voluntary basis. This allows for comprehensive
1103 and unbiased resistome profiling, enabling the detection of both known and emerging ARGs within

1104 microbial communities and the adaptation of qPCR monitoring targets to the evolving antimicrobial
1105 resistome. As a result, it enhances our understanding on the current environmental AMR profile and
1106 evolving resistance mechanisms. Traditional molecular techniques, employed by most European
1107 countries, such as qPCR and culture-based approaches, are unable to provide these insights.

1108 Metagenomics offers:

1109 **Comprehensive Resistome Profiling:** Metagenomics offers the ability to reconstruct a wide array of
1110 novel ARGs, offering an accurate and holistic picture of the resistome, that is more comprehensive
1111 than other approaches (10). This capability is crucial for identifying emerging threats that currently
1112 could go undetected by targeted methods.

1113 **Agnostic Methodology:** It allows for an unbiased approach which extends our knowledge of ARGs
1114 beyond the currently known ones. In the future, reconstruction of ARGs can happen directly from
1115 metagenomic data even with a low sequence similarity to known ARGs. Currently, this is still under
1116 research, as it requires extensive bioinformatics capability.

1117 **Contextual Information:** Long metagenomic read can provide some contextual data, such as on
1118 plasmids, integrons and co-occurrence of ARGs, which is essential for risk assessment and
1119 understanding the broader ecological impact of AMR.

1120 **Adaptability and Scalability:** As bioinformatics and sequencing technologies advance, metagenomics
1121 remains adaptable, ensuring its relevance and scalability for future surveillance needs. The
1122 developments in AI and automated bioinformatics of recent years, will help to process and analyse
1123 larger quantities of complex data.

1124 There are also some limitations as compared to other techniques. Unless using alternative
1125 metagenomic sequencing approaches (e.g. Hi-C metagenomics), 2nd generation short reads are known
1126 to be limited in linking resistance genes to their bacterial host. Furthermore, there are frequently
1127 repetitive regions surrounding resistance genes making it difficult to identify its mobile genetic
1128 element, such as plasmids. 3rd generation sequencing technologies, at least in part, may overcome
1129 these difficulties. Finally, metagenomic sequencing is resource-intensive, both in terms of financial cost
1130 and data processing requirements (Annex 5).

1131 Monitoring is recommended on a monthly basis for both influent and effluent samples from each
1132 WWTP, resulting in a total of 24 samples per year. Biannual monitoring strikes a balance between
1133 collecting enough data to build a robust knowledge base, to manage the practical constraints of
1134 extensive sequencing and to allow informed decision-making. Furthermore, conducting biannual
1135 metagenomic analyses can help capture of potential seasonal variations on the distribution and
1136 evolution of the antimicrobial resistance. This frequency enables to identify patterns linked to seasonal
1137 factors such as fluctuations in temperature, rainfall, and human activity.

1138 Financial and technical help will be provided to Member States wanting to undertake metagenomics
1139 as part of the newly established EU Sentinel System. This includes access to standardised protocols,
1140 expert guidance, and personnel training. Such assistance will also help Member States build long-term
1141 technical capacity and integrate metagenomic data into routine monitoring alongside qPCR
1142 methodology.

1143

1144 **9.2 Cost considerations**

1145 The cost figures presented here are simplified estimates for assay analysis only; a detailed breakdown
1146 of all associated costs is provided in Annex 5.

1147 For the proposed harmonised monitoring of urban wastewater, monthly sampling of both influent and
1148 effluent at each wastewater treatment plant (WWTP) is recommended, resulting in 24 samples per
1149 year per plant. This sampling frequency balances temporal resolution, resource allocation, and
1150 surveillance quality.

1151 **Annual Cost Estimates:**

1152 Based on published data for standard qPCR assays targeting antimicrobial resistance genes (ARGs), the
1153 analytical cost per assay is estimated to range between approximately €100 and €300.³⁶
1154 Applying this range to the proposed sampling strategy, the annual analytical cost per WWTP would be:

1155
$$24 \text{ samples/year} \times \text{€}100\text{--}\text{€}300 \approx \text{€}2,400\text{--}\text{€}7,200 \text{ per WWTP per year}$$

1156 These figures reflect assay costs only and assume single-gene or small multiplex panels, as
1157 recommended for the harmonised EU approach.

1158 They do not include other essential activities such as (i) sample collection and handling at the WWTP,
1159 (ii) transportation to the laboratory, (iii) personnel costs, (iv) reporting and data management, or (v)
1160 laboratory accreditation and quality assurance measures. A more comprehensive breakdown of both
1161 capital expenditures (CapEx) and operational expenditures (OpEx), including sampling, transport, and
1162 additional laboratory processing costs, is provided in Annex 5.

1163

1164 **Method Selection and Rationale**

1165 - Cultivation-free qPCR is proposed as the standard method because it enables rapid, sensitive, and
1166 reproducible detection of ARGs directly from wastewater DNA, without the labour, time, and
1167 variability associated with culture-based methods.

1168 - Alternative methods, such as metagenomics, provide broader resistome profiling but remain more
1169 expensive (€500–€1,500 per sample) and require specialised bioinformatics support³⁷. These can
1170 be adopted voluntarily by Member States.

1171 Other methods (e.g., ddPCR, cultivation-based PCR, lab-on-a-chip) are informative but most expensive
1172 or experimental and, are not recommended for a baseline EU surveillance programme³⁸. Overall, qPCR
1173 remains the most cost-effective for rapid and targeted analyses, while ddPCR is favoured for precise
1174 quantification, particularly for low-copy-number targets. Cultivation-based methods are useful when
1175 viability and strain differentiation are necessary, but at the cost of increased time and resources.
1176 Institutions with high-throughput needs or involved in detailed microbiome or resistome profiling may
1177 have the capacity for combinations of these methods to optimise cost and data quality.

³⁶ [Current and Future Technologies for the Detection of Antibiotic-Resistant Bacteria - PMC](#)

³⁷ [CARPDM: cost-effective antibiotic resistome profiling of metagenomic samples using targeted enrichment - PubMed](#)

³⁸ [Monitoring-AMR-in-the-EU.pdf](#)

1178 For a more detailed discussion and overview on the estimation and evaluation of costs for different
1179 analytical methods for monitoring AMR in wastewater, please refer to the Annex 5.

1180 **9.3 Additional considerations**

1181 **Handling of wastewater samples**

1182 Sampling kits are available to filter wastewater samples, followed by either DNA extraction on-site or
1183 the cold shipment of samples to specified laboratories. By trapping bacteria in filters under nutrient-
1184 free, dry, and cold or frozen conditions, the likelihood of significant changes in the bacterial community
1185 is minimised, better reflecting the conditions at the time of sample collection. In general, it is a more
1186 accessible and feasible method for sample collection. Centrifugation and subsequent concentration of
1187 samples may be another viable option.

1188 Freezing of wastewater samples is a common practice for storage reasons and possible retrospective
1189 analyses. However, the thawing process may compromise the integrity of the samples. For example,
1190 cell lysis during thawing can lead to an inaccurate representation of the bacterial state compared to
1191 the time of sampling. Therefore, this approach is not recommended

1192 **9.4 The value of other technologies in AMR monitoring**

1193 ***High-throughput quantitative PCR (HT-qPCR)***

1194 HT-qPCR is an qPCR approach which has an increased speed, sensitivity and specificity, and throughput
1195 compared to traditional qPCR methods. It allows for the analysis of a large number of samples or
1196 targets simultaneously. It excels in detecting and quantifying specific resistance genes, even at low
1197 abundance, 10^{-4} to 10^{-5} in proportion to the 16S rRNA genes³⁹. HT-qPCR provides standardised
1198 quantitative measurements, enabling consistent data collection and quick results, which are essential
1199 for timely public health interventions, such as identifying hotspots and trends, issuing clinical alerts, or
1200 taking other actions to reduce the risk of AMR spread⁴⁰.

1201 In addition, it supports the evaluation of the performance of WWTPs in removing AMR genes before
1202 discharge, helping to minimise their release into the water environment. Yet, it is not to be forgotten
1203 that HT-qPCR also has its limits, notably the possibility for false positive signals due to the lack of
1204 probes, which can be problematic if used for public health and environmental signals⁴¹.

1205 Another example of HT-qPCR technology relevant to public health is the SmartChip qPCR system, which
1206 efficiently analyses a wide range of samples and genes, from 12 up to 384 genes simultaneously⁴².
1207 However, a higher number of targets results in a great increase in cost per sample. SmartChip qPCR
1208 provides standardised quantitative measurements, supported by benchmarking indexes for AMR load
1209 in European wastewater samples. SmartChip qPCR provides standardised quantitative measurements,
1210 supported by benchmarking indexes for AMR load in European wastewater samples.

³⁹ [Contributions and Challenges of High Throughput qPCR for Determining Antimicrobial Resistance in the Environment: A Critical Review - PMC](#)

⁴⁰ [Rapid Methods for Antimicrobial Resistance Diagnostics - PMC](#)

⁴¹ [High-throughput qPCR profiling of antimicrobial resistance genes and bacterial loads in wastewater and receiving environments - PubMed](#)

⁴² [SmartScreen-AIS: A high-throughput qPCR chip for nationwide surveillance of aquatic invasive species](#)

1211 **Culture-based methods**

1212 Culture-based approaches, which involve growing and testing bacterial isolates, continue to play a role
1213 in antimicrobial resistance surveillance, particularly for confirming phenotypic resistance. Culturing
1214 methods, which can offer as important complementary information and can act as an extension to the
1215 proposed monitoring strategy. Firstly, high throughput methods cannot address treatment
1216 effectiveness as, at the DNA level, they measure genes from both live and dead bacteria. These can be
1217 differentiated on the RNA level. There are modified culture methods emerging on the market which
1218 permit measurement of trends over time, while simultaneously measuring treatment effectiveness by
1219 accounting only for live bacteria and measuring exposure risk due to live AMR bacteria still in water
1220 post-treatment. These functions that PCR cannot fulfill can inform strategies to interrupt
1221 environmental transmission pathways and mitigate illness and mortality. There are modified culture
1222 methods emerging on the market which permit measurement of trends over time, while
1223 simultaneously measuring treatment effectiveness by accounting only for live bacteria and measuring
1224 exposure risk due to live AMR bacteria still in water post-treatment. These functions that PCR cannot
1225 fulfill can inform strategies to interrupt environmental transmission pathways and mitigate illness and
1226 mortality.

1227 In addition, modified culture methods can re-purpose existing surveillance and regulatory
1228 infrastructure. In fact, ISO methods are already in use in Europe and around the world. Laboratories
1229 with these methods in place can easily accommodate changes with minimal training and investment.
1230 This is especially pertinent to low and middle-income countries, where laboratory equipment and
1231 skilled personnel for plating methods can have limited and long sample transportation times make it
1232 difficult to meet the sample processing requirement (<8 hours from sampling).

1233 **Harmonising metagenomic sequencing**

1234 Metagenomics provides a comprehensive, unbiased approach to assess complete AMR profiles.
1235 However, results can vary depending on the specific analysis workflow used, including the choice of
1236 computational tools, databases, and data processing steps.

1237 **Sequencing technology:** Technologies from different providers such as Illumina, Nanopore, or PacBio
1238 can deliver method-specific results.

1239 **Data processing:** This includes factors such as the depth of sequencing, the bioinformatic pipeline,
1240 and the AMR database used to process the data.

1241 **Data storage and IT infrastructure:** Hosting large quantities of metagenomic data can be expensive for
1242 single institutions. Leveraging existing infrastructure, such as European Centre for Disease
1243 Prevention and Control's (ECDC) EpiPulse or developing tools like DG Health Emergency
1244 Preparedness and Response Authority's (HERA) Advanced Technology for Health Intelligence and
1245 Action IT System (ATHINA) Platform, could mitigate costs, support data sharing and collaboration.
1246 Both ECDC and HERA expressed their interest in receiving such data, but further agreements are
1247 needed. The European Nucleotide Archive (ENA) is another feasible option.

1248 **Sharing of metadata:** While raw sequencing data can generally be made open access without major
1249 constraints, the associated metadata linked to urban wastewater systems may raise sensitivities.
1250 The metadata referenced here includes not only standard technical information reported under
1251 the Urban Waste Water Treatment Directive (e.g., treatment capacity, influent and effluent
1252 characteristics), which is often publicly available, but also more detailed or sensitive contextual
1253 data. This can encompass socio-economic information, specific infrastructure details, or
1254 operational parameters that wastewater operators may be reluctant to share openly due to
1255 concerns around infrastructure security or commercial confidentiality. Addressing these concerns
1256 and facilitating the participation of such actors is essential, especially when data linked to
1257 regulatory or policy frameworks, such as the European Water Acquis, must be accessible to the
1258 public.

1259 **Rise of artificial intelligence (AI)**

1260 Complementing detection practices, machine-learning models can be trained on available datasets to
1261 predict the presence and abundance of specific ARGs in wastewater from defined regions. This
1262 approach can help prioritise sampling, flag anomalous results for review, and provide early warnings
1263 of emerging hotspots. However, the extent to which such models can be applied depends on the
1264 availability and quality of data generated under rUWWTD monitoring requirements.

1265 **Developments in quality assurance control (AQC)**

1266 The review findings underscore that the imperative for standardisation and robust analytical quality
1267 control (AQC) tools in monitoring antimicrobial resistance (AMR) in wastewater has never been
1268 greater. The adoption of standardised methodologies is critical to ensure consistency and
1269 comparability of data across diverse studies and Member States, forming the foundation for effective
1270 public health strategies and policies aimed at mitigating the spread of AMR. Addressing this urgent
1271 requirement, the Joint Research Centre (JRC) has initiated efforts to expand its catalogue of reference
1272 materials tailored for wastewater surveillance. In partnership with the Institut Pasteur, the JRC is
1273 developing certified reference materials (CRMs) designed to support both PCR-based methods and
1274 metagenomic approaches. A key feature of this development is the integration of an engineered
1275 plasmids with well-characterised ARG sequences. These CRMs function as a validated standard
1276 enabling laboratories to calibrate their assays and ensure the analytical accuracy and inter-laboratory
1277 reproducibility of ARG detection in wastewater monitoring. The adoption of such reference materials
1278 is anticipated to harmonise molecular analyses across Member States, fostering greater comparability
1279 of AMR data. This initiative significantly strengthens the JRC's capacity to provide standardised tools,
1280 thereby facilitating more accurate, reliable assessments of AMR in wastewater and supporting
1281 harmonised surveillance outcomes at both the European and global levels.

1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313

10.Next steps

The next steps towards supporting the development of the implementing acts for the recast UWWTD include:.

Experimental evaluation:

Although several methods for AMR monitoring are currently in use, this experimental phase is necessary to systematically assess the proposed harmonized methodology’s performance in terms of analytical limits, data quality, reliability, costs, and operational feasibility. This evaluation will clarify any existing uncertainties and ensure the method is fit-for-purpose across diverse environmental contexts.

Method optimisation:

Based on results from experimental evaluation, the most feasible and robust methods will be further optimized. This includes improving selectivity, repeatability, accuracy, and overall robustness to finalize standardized testing protocols (SOPs). Optimization ensures consistent and high-quality data generation across laboratories.

Method validation:

The Joint Research Centre (JRC) will conduct targeted method validation to establish interlaboratory reproducibility and generate documentary guidelines. This step is vital to confirm the method’s reliability irrespective of the testing laboratory and to provide performance benchmarks.

Stakeholder consultation:

Consultations with key expert stakeholders, including the Eionet AMR Working Group, the Transatlantic Taskforce on Antimicrobial Resistance (TATFAR), and active Member States, will discuss the experimental outcomes. Topics will include sampling design, cost estimates, scalability, data management, result interpretation, communication strategies, and overall acceptability of the methodology. This engagement ensures transparency and broad consensus on next steps.

Drafting the implementing act:

Scientific and technical input from JRC based on the above stages will support the drafting of the legal implementing act, embedding the methodology within the EU framework.

1314 **List of abbreviations and definitions**

Abbreviations

AI	Artificial intelligence
AMR	Antimicrobial resistance
AOP	Advanced oxidation processes
AQC	Analytical quality control
ARGs	Antibiotic resistance genes
ASTM	American Society for Testing and Materials
ATHINA	Advanced Technology for Health Intelligence and Action IT System
CARD	Comprehensive Antibiotic Resistance Database
CEN	European Committee for Standardisation (Comité Européen de Normalisation)
CFU	Colony forming unit
CHP	Combined heat and power
CLSI	Clinical and Laboratory Standards Institute
CPE	Carbapenemase-producing Enterobacterales
cpMLST	Core plasmid Multi-Locus Sequence Typing
ddPCR	Digital droplet Polymerase Chain Reaction
DG	Directorate-General
DG ENV	Directorate-General for Environment
DG JRC	Directorate-General Joint Research Centre
DNA	Deoxyribonucleic acid
dPCR	Digital Polymerase Chain Reaction
ECDC	European Centre for Disease Prevention and Control
EEA	European Environment Agency
EML List	WHO Model List of Essential Medicines
ENA	European Nucleotide Archive
ESBL	Extended-spectrum beta-lactamase
ESBL-Ec	ESBL-producing <i>Escherichia coli</i>
EU	European Union
EUCAST	European Committee on Antimicrobial Susceptibility Testing
EU-JAMRAI	European Union Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections
EU-WISH	EU-Wastewater Integrated Surveillance for Public Health
FAO	Food and Agriculture Organization
FPKM	Fragments per Kilobase per Million reads
GLASS	Global Antimicrobial Resistance and Use Surveillance System
HaDEA	European Health and Digital Executive Agency
HERA	Health Emergency Preparedness and Response Authority
HGT	Horizontal gene transfer
HSC	Health Security Committee
HT	High throughput
ISO	International Organization for Standardisation
JA	Joint Action

MGEs	Mobile genetic elements
MIA List	WHO List of Medically Important Antimicrobials
MRSA	Methicillin-resistant <i>Staphylococcus aureus</i>
NGS	Next-Generation Sequencing
OIE	World Organisation for Animal Health
NUTS	Nomenclature of territorial units for statistics
PCR	Polymerase chain reaction
PE	Population equivalent
qPCR	quantitative Polymerase Chain Reaction
rRNA	Ribosomal ribonucleic acid
RT-qPCR	Reverse Transcription-quantitative Polymerase Chain Reaction
UN	United Nations
UV	Ultraviolet
WES	Wastewater and Environmental Surveillance
WGS	Whole genome sequencing
WHO	World Health Organization
WOAH	World Organisation for Animal Health
WWTP	Wastewater treatment plant
2024 BPPL	WHO Bacterial Priority Pathogens List 2024

1315

Definitions

Metagenomics	The study of the structure and function of entire nucleotide sequences isolated and analysed from all the organisms (typically microbes) in a bulk sample.
Shotgun metagenomics	A culture-independent technique for DNA sequencing technique used to analyse the genetic material of microbial communities.
16S rRNA gene sequencing	A method used to identify and classify bacteria and archaea by analysing the highly conservative 16S ribosomal RNA gene.
Metatranscriptomics	A method used to study the gene expression of microbial communities within specific environments by quantify all the mRNA transcripts produced by the microorganisms
Urban wastewater	means any of the following: (a) domestic wastewater; (b) the mixture of domestic wastewater and non-domestic wastewater; (c) the mixture of domestic wastewater and urban runoff; (d) the mixture of domestic wastewater, non-domestic wastewater and urban runoff
Agglomeration	‘agglomeration’ means an area where the population expressed in population equivalent, combined or not with economic activities, is sufficiently concentrated for urban wastewater to be collected and conducted to one or more urban wastewater treatment plants or to one or more final discharge points
1 population equivalent	“1 population equivalent” or ‘(1 p.e.)’ means the organic biodegradable load per day, having a five-day biochemical oxygen demand (BOD5) of 60 g of oxygen per day;
Sludge’	‘sludge’ means organic and inorganic residue resulting from the treatment of urban wastewater from an urban wastewater treatment plant, excluding grit, grease, other debris and any other screenings and residues from the pre-treatment step;

One Health	'One Health' means One Health as defined in Article 3, point (7), of Regulation (EU) 2022/2371 of the European Parliament and of the Council
------------	--

1316

1317 **Annexes**

1318 **Annex 1: Prompt template for data extraction**

1319 Comprehensive Search Prompt:

1320 "Anti-microbial resistance monitoring in urban wastewater" AND "executive summary findings"

1321 "Background and motivation for AMR research" OR "objectives and research questions in AMR
1322 studies"

1323 "Methodologies for sampling protocols in wastewater"

1324 a. "Overview of sampling protocols for AMR in wastewater"

1325 b. "Strategies for sampling AMR in water environments"

1326 c. "Types of environmental samples for AMR"

1327 d. "Use of sampling equipment and techniques in AMR detection"

1328 e. "Quality assurance and control in sampling protocols"

1329 f. "Country-specific AMR sampling methodologies"

1330

1331 "Pre-treatment procedures in AMR testing"

1332 a. "Overview of pre-treatment in AMR analysis"

1333 b. "Filtration techniques for AMR samples"

1334 c. "Chemical pre-treatment for AMR detection"

1335 d. "Concentration methods for enhancing AMR detection"

1336 e. "Alternative pre-treatment strategies in AMR analysis"

1337 f. "Country-specific insights on pre-treatment methodologies"

1338

1339 "Detection methods for antimicrobial resistance in wastewater"

1340 a. "Overview of detection methods in AMR research"

1341 b. "PCR techniques in detecting AMR"

1342 c. "Next-Generation Sequencing (NGS) for AMR"

1343 d. "High-throughput screening methods for AMR detection"

1344 e. "Bioinformatics and data analysis in AMR monitoring"

1345 f. "Implementation of detection methods across countries"

1346

1347

- 1348 "Data analysis in AMR studies"
- 1349 a. "Statistical analysis of AMR data"
- 1350 b. "Interpretation of AMR results and findings"
- 1351
- 1352 "Results on ARGs and antibiotic resistance"
- 1353 a. "Overview of detected ARGs in various environments"
- 1354 b. "Comparative analysis of AMR across different countries"
- 1355
- 1356 "Discussion on regional variations in antibiotic resistance genes (ARGs)"
- 1357 a. "Implications of AMR variations for public health"
- 1358 b. "Challenges and limitations in AMR research and detection"
- 1359
- 1360 "Conclusions on AMR research"
- 1361 a. "Summary of key findings on AMR in wastewater"
- 1362 b. "Future research directions in tackling AMR"
- 1363
- 1364 "Recommendations for policy and practice"
- 1365 a. "Policy implications of AMR research findings"
- 1366 b. "Strategic actions for monitoring and control of AMR"
- 1367
- 1368 "References and appendices in AMR research reports"
- 1369 a. "Detailed tables and supplementary figures for AMR studies"
- 1370 b. "Supplementary materials supporting AMR research"
- 1371
- 1372 First prompt of national studies and specific applications:
- 1373 "Conduct a comprehensive review of the attached scientific publication focused on detecting
- 1374 antimicrobial resistance (AMR) in water and wastewater. Specifically, identify and list all mentioned
- 1375 antimicrobial resistances (AMR) and antibiotic resistance genes (ARGs) discussed in the papers.
- 1376 Examine:
- 1377 Sampling Methods:
- 1378 Detailed methodologies used for sampling water and wastewater for AMR analysis.
- 1379 Techniques and equipment employed in the collection of samples.

1380

1381 Sample Pre-treatment:

1382 Pre-treatment procedures applied to samples prior to AMR testing, including any filtration,
1383 chemical, or concentration methods.

1384 Detection Methods:

1385 Various detection techniques used for identifying AMR in water and wastewater.

1386 Efficiency and applicability of techniques such as PCR, next-generation sequencing, and high-
1387 throughput screening.

1388

1389 Ensure the review highlights the standardised practices as well as any innovative or country-specific
1390 approaches discussed in the publications. List ALL AMR, ARGs and related parameters discussed in
1391 this publication and highlight specific aspects with regard to the aforementioned single analytical
1392 steps"

1393

1394 Second prompt of national studies and specific applications:

1395 List all AMR and ARGs discussed in this publication

1396

1397 Final prompt of national studies and specific applications:

1398 Considering the above provide now a comprehensive summary of the report.

1399
1400
1401
1402

Annex 2: Summary of extracted data from reviewed literature.

Table A1. Summary of extracted data for EU countries including references, sampling and analytical methods, targeted ARGs, standardisation status, and monitoring descriptors.

Country	Reference	Sampling and Analytical Methods	ARGs Monitored	Standardisation	Descriptors for Monitoring
Austria	(30,31)	<p>Sampling Methods: Comparison of sampling schemes, such as grab samples and composite samples, including flow- and volume-proportional samples.</p> <p>Analytical Methods: qPCR, dPCR, HT-qPCR, shotgun metagenomics, and hybrid capture-based sequencing.</p>	<p><i>sul1</i>, <i>ermB</i>, <i>tetW</i>, <i>vanA</i>, <i>blaTEM-1</i>, <i>nptII</i>, <i>nptIII</i>.</p>	<p>Emphasis on the development of standardised protocols and workflows for sampling, sample processing, molecular detection and bioinformatics analyses to ensure data reliability and inter-laboratory comparability.</p> <p>Focus aligns with the Urban Wastewater Treatment Directive (EU) 2024/3019 (Article 17(3)), WHO GLASS initiative and One Health frameworks.</p>	<p>Absolute ARG gene copies per mL of wastewater.</p> <p>Relative ARG abundance normalised to 16S rRNA gene copies per mL.</p> <p>Calculations of log reduction of ARG abundance between influent and effluent.</p>
Belgium	(6,32)	<p>Sampling Methods: Structured grab and composite sampling strategies from influent, effluent and receiving waters. Advocates for spatially distributed sampling.</p> <p>Analytical Methods: culture-based methods, complemented with ddPCR, qPCR and metagenomic sequencing.</p>	<p><i>sul1</i>, <i>sul2</i>, <i>aadA</i>, <i>aac(3)-IV</i>, <i>blaCTX-M</i>, <i>blaNDM</i>, <i>blaSHV</i>, <i>blaKPC-2/3</i>, <i>ermB</i>, <i>ermF</i>, <i>qnrS</i>, <i>tetO</i>, <i>tetM</i>, <i>vanA</i>.</p>	<p>Focus on developing reproducible methodological workflows, harmonising molecular detection protocols and reporting formats to ensure standardisation across global research efforts.</p> <p>Calls for a multi-indicator approach aligned with the Urban Wastewater Treatment Directive (EU) 2024/3019 and the One Health strategy.</p> <p>No specific international standards are referenced.</p>	<p>Bacterial count as CFU per 100 mL of wastewater.</p> <p>Absolute ARG gene copies per mL of wastewater.</p> <p>Relative ARG abundance normalised to 16S rRNA gene copies per mL, per ng DNA, per day per PE.</p> <p><i>int11</i> included: marker for HGT and spread of ARGs.</p> <p>Calculations of log reduction of ARG abundance between influent and effluent.</p>

Country	Reference	Sampling and Analytical Methods	ARGs Monitored	Standardisation	Descriptors for Monitoring
Bulgaria	(33,34)	<p>Sampling Methods: Composite samples from influent and effluent points as well as from downstream of the WWTP discharge.</p> <p>Analytical Methods: Shotgun metagenomic sequencing.</p>	<p><i>blaCTX-M</i>, <i>blaKPC-2/3</i>, <i>tetM</i>, <i>tetC</i>, <i>tetO</i>, <i>tetW</i>, <i>tetQ</i>, <i>tetX</i>, <i>ermB</i>, <i>ermF</i>, <i>mphE</i>, <i>msrE</i>, <i>vanA</i>, <i>sul1</i>, <i>sul2</i>, <i>aac(3)-IV</i>, <i>cfxA3</i>, <i>cfxA6</i>.</p>	<p>Emphasis on adopting standardised methodologies for consistent sampling, molecular detection, standardised bioinformatics pipelines and reproducible metagenomic workflows.</p> <p>Focus on benchmarking bacterial DNA extraction for metagenomic analysis.</p> <p>MetaCompare2.0 used to calculate the resistome risk score.</p> <p>No specific international standards are referenced.</p>	<p><i>int11</i> included: marker for HGT and spread of ARGs.</p> <p>Calculations of log fold change of bacterial taxa as a result of applied enrichment methods.</p>
Finland	(35)	<p>Sampling Methods: Sampling from influent untreated water. and since 2025 from treated wastewater effluents.</p> <p>Analytical Methods: culture-based enumeration, ddPCR, in-house qPCR, HT-qPCR, metagenomics.</p>	<p><i>blaCTX-M</i>, <i>blaTEM</i>, <i>blaKPC-2/3</i>, <i>blaOXA</i>, <i>blaVIM</i>, <i>blaNDM</i>, <i>AmpC</i>, <i>mecA</i>, <i>tetM</i>, <i>ermB</i>, <i>vanA</i>, <i>sul2</i>, <i>aac(3)-IV</i>.</p>	<p>Importance of harmonising detection protocols for consistent results yet does not mention specific standards by international bodies.</p> <p>Stress metadata standardisation such as sample timing, concentration methods and analytical workflows.</p> <p>Report initiatives like the Global Sewage Surveillance Consortium.</p> <p>Participate in international AMR monitoring method development in ISO/TC 147/SC 4 "Microbiological methods" (Secretariat: DIN; Committee manager: Joana Gericke)</p>	<p>Bacterial count as CFU per 100 mL of wastewater.</p> <p>Absolute ARG gene copies per mL of wastewater.</p> <p>Relative ARG abundance normalised to 16S rRNA gene copies per mL, or total DNA per mL.</p>

Country	Reference	Sampling and Analytical Methods	ARGs Monitored	Standardisation	Descriptors for Monitoring
France	(36–41)	<p>Sampling Methods: Composite samples of influent and effluent urban and hospital wastewater, surface water, sludge, river, and groundwater sites using auto-samplers and manual collection.</p> <p>Analytical Methods: culture-based methods, HT-qPCR, 16S rRNA sequencing, and metatranscriptomics.</p>	<p><i>blaRCP, blaLCR, blaFOX, blaNPS, blaTEM, aac(3)-Ib/aac(6)-Ib, aadB, aph(3''), aph(6), aac(3)-IId, mph, catB3, ermF, vanA, tetQ, sul1.</i></p>	<p>Propose a national framework within the One Health approach for harmonised methodology for ARG detection.</p> <p>Establishment of "AMR-Env" group, as part of the "PROMISE" project launched under the French Priority Research Program on Antimicrobial Resistance for standardised and harmonised collection and analysis methods in natural environments.</p> <p>Adhere to standardised protocols for sample pre-treatment, following ISO standards for measurement of micropollutants and ARGs.</p> <p>No specific mention of other international bodies like CEN or ASTM in the context of AMR in urban wastewater.</p>	<p>Concentration of antibiotic residues as ng/L</p> <p>Absolute ARG gene copies per mL of wastewater.</p> <p>Relative ARG abundance normalised to 16S rRNA gene copies per mL, copies per total DNA per mL or per bacterial cell.</p> <p><i>int11, int12, int13</i> included: markers for HGT and spread of ARGs.</p> <p>Include metadata descriptors, such as sampling date/location, methods used, normalisation procedures.</p>
Germany	(13,42–92)	<p>Sampling Methods: 24-hour composite and grab samples from urban, hospital and agricultural wastewater influents and effluents, surface waters, soils, sediments, biofilms, sludge, and drinking water reservoirs.</p> <p>Analytical Methods: culture-based methods, qPCR, dPCR, cultivation on selective agar media and subsequent WGS of isolates.</p>	<p><i>blaTEM, blaCTX-M, blaOXA-48, blaVIM, blaNDM, blaKPC, sul1, tetM, ermB, mcr-1, vanA.</i></p>	<p>Large-scale, multi-site and multi-country sampling efforts are undertaken to establish prevalence baselines.</p> <p>Recognise the need for standardised methodologies, but specific adherence to standards set by international bodies such as CEN, ISO, or ASTM is not mentioned.</p> <p>Have launched the NORMAN ARB&ARG database to promote data sharing, method alignment, and harmonised surveillance frameworks.</p>	<p>Absolute ARG gene copies per mL of wastewater.</p> <p>Relative ARG abundance normalised to 16S rRNA gene copies per mL.</p> <p>Presence of specific ARGs and AMR bacteria is used as indicators of pollution and potential health risks.</p>

Country	Reference	Sampling and Analytical Methods	ARGs Monitored	Standardisation	Descriptors for Monitoring
Hungary	(93)	<p>Sampling Methods: 24-h automated sampler composite influent wastewater samples. Grab samples from airport.</p> <p>Analytical methods: Culture-based methods, RT-qPCR with both commercially available and in-house methods.</p>	<p><i>blaCTX-M1</i>, <i>blaNDM</i>, <i>blaKPC</i>, <i>blaOXA-48</i>, <i>vanA</i>, <i>vanB</i>.</p>	<p>Standardisation approaches are not discussed.</p>	<p>Absolute ARG gene copies per L of wastewater.</p>
Ireland	(94–101)	<p>Sampling Methods: Collection of influent and effluent wastewater from municipalities and hospitals.</p> <p>Analytical Methods: Culture-based detection, RT-PCR, cultivation followed by WGS.</p>	<p><i>blaTEM</i>, <i>blaSHV</i>, <i>blaCTX-M</i>, <i>blaOXA-48</i>, <i>blaNDM-5</i>, <i>blaKPC-2</i>, <i>blaIMP</i>, <i>blaVIM</i>, <i>mcr-8</i>, <i>mcr-9</i>, <i>sul1</i>, <i>sul2</i>, <i>tetA</i>, <i>aadA</i>, <i>cmlA</i>.</p>	<p>Standardised guidelines such as those from EUCAST and CLSI are followed for antibiotic susceptibility testing.</p> <p>Recognise the need for systematic, standardised protocols to enable reliable national and transnational surveillance, and support One Health integration.</p> <p>No indication of adherence to standards set by international bodies such as CEN, ISO, or ASTM.</p>	<p>Bacterial count as CFU per 100 mL of wastewater.</p> <p>Absolute ARG gene copies per mL of wastewater.</p> <p>Relative ARG abundance normalised to 16S rRNA gene copies per mL.</p> <p><i>int11</i> included: marker for HGT and spread of ARGs.</p> <p>Include metadata descriptors, such as sampling date/location, methods used, and susceptibility thresholds.</p>
Italy	(102–104)	<p>Sampling Methods: Composite sampling over 24 hours.</p> <p>Analytical Methods: culture-based methods, dPCR, RT-qPCR.</p>	<p><i>blaCTX-M</i>, <i>blaKPC</i>, <i>vanA</i>, <i>qnrS</i>.</p>	<p>Development of standardised protocols for AMR monitoring in wastewater through national level working groups. Protocols have been finalised.</p> <p>EUCAST clinical breakpoints used to define the resistance phenotypes and EUCAST algorithms for sensibility profiles.</p>	<p>Absolute ARG gene copies per mL of wastewater.</p> <p>Relative ARG abundance normalised to 16S rRNA gene copies per mL.</p> <p><i>int11</i> included: marker for HGT and spread of ARGs.</p>

Country	Reference	Sampling and Analytical Methods	ARGs Monitored	Standardisation	Descriptors for Monitoring
Netherlands	(105–113)	<p>Sampling Methods: Automatic 24-hour flow-proportional composite sampling from influent and effluent municipal and hospital wastewater.</p> <p>Analytical Methods: Culture-based methods, HT-qPCR, culturing followed by WGS, shotgun metagenomics.</p>	<p><i>blaOXA-48</i>, <i>blaCTX-M</i>, <i>blaNDM</i>, <i>blaKPC</i>, <i>ermB</i>, <i>sul1</i>, <i>sul2</i>, <i>vanA</i>, <i>vanB</i>, <i>mcr-1</i>, <i>tetM</i>, <i>tetA</i>, <i>cmlA</i>, <i>qnrS</i>, <i>korB</i>.</p>	<p>Surveillance of AMR is based on consistent national protocols put forwards by the Dutch National Institute for Public Health and the Environment (RIVM) to support monitoring of longitudinal trends.</p> <p>The documents do not explicitly mention the involvement of international standardisation bodies such as CEN, ISO or ASTM.</p>	<p>Relative ARG abundance normalised to 16S rRNA gene copies per mL.</p> <p>Calculations of log reduction of ARG abundance between influent and effluent.</p> <p><i>int11</i> included: marker for HGT and spread of ARGs.</p>
Portugal	(114–117)	<p>Sampling Methods: 24-hour composite sampling and grab sampling from influents of WWTPs and hospitals. Deploy fractionated sampling.</p> <p>Analytical Methods: Culture-based isolation followed by antibiotic susceptibility testing (Kirby–Bauer disk method), dPCR, qPCR, shotgun metagenomic sequencing.</p>	<p><i>blaTEM</i>, <i>blaSHV</i>, <i>blaCTX-M</i>, <i>blaCMY</i>, <i>mecA</i>, <i>vanA</i>, <i>vanB</i>, <i>mcr-1</i>.</p>	<p>Standardisation approaches are not discussed.</p>	<p>Bacterial count as CFU per 100 mL of wastewater.</p> <p>Absolute ARG gene copies per L of wastewater.</p> <p>Relative ARG abundance normalised to 16S rRNA gene copies per mL.</p> <p>Fractional quantification to distinguish ARG presence in bacteria versus phage DNA for vector transfer analysis.</p>

Country	Reference	Sampling and Analytical Methods	ARGs Monitored	Standardisation	Descriptors for Monitoring
Sweden	(24,105,118–134)	<p>Sampling Methods: Composite sampling over 24 hours using time-proportional and flow-proportional techniques from influent wastewater.</p> <p>Analytical Methods: Culture-base methods, qPCR, culturing followed by WGS, metagenomic sequencing.</p>	<p><i>blaNDM,</i> <i>blaOXA-48,</i> <i>blaKPC, blaVIM,</i> <i>blaIMP, blaCTX-M,</i> <i>blaTEM, blaSHV,</i> <i>tetA,</i> <i>mcr-1,</i> <i>sul1, sul2,</i> <i>qnr</i> genes, <i>mphA.</i></p>	<p>ARG annotations were harmonised using the CARD and ResFinder.</p> <p>The documents do not explicitly mention the involvement of international standardisation bodies such as CEN, ISO or ASTM.</p>	<p>Bacterial count as CFU per mL of wastewater.</p> <p>Absolute ARG gene copies per L of wastewater.</p> <p>Relative ARG abundance normalised to 16S rRNA gene copies per mL.</p> <p>Fragments per Kilobase per Million reads (FPKM) used to normalise library size in metagenomic analysis.</p> <p>Measure of unique ARGs per sample via Chao richness estimators.</p>

1404

Source: EC-JRC

1405 **Annex 3: National Obligations for AMR Monitoring in Aquatic Systems: EU-27 Comparative Analysis**

1406

1407 **Table A2.** Overview of national obligations and monitoring practices for antimicrobial resistance (AMR) in aquatic systems across EU-27 member states.

1408 The dataset may not reflect all ongoing initiatives due to variability in national reporting and evolving legislations.

Country	National Obligation	EU Linkage	National Projects / Instruments	Additional References
Austria	No specific binding legal mandate for AMR-related water. Legally binding groundwater monitoring system (Water Rights Act 1959) on broad water quality parameters (such as pH, nitrates, heavy metals, pesticides)	1. European Antimicrobial Resistance Surveillance Network (EARS-Net) 2. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 3. EU One Health Action Plan against AMR	1. National Action Plan for Antibiotics Resistance (NAP-AMR) 2. The PIER (Public Health Impact of Exposure to Antibiotic Resistance in Recreational Waters) 3. Infection Prevention and Control (PROHYG 2.0) 4. Antimicrobial Stewardship Programme (ASP)	1. AURES (Antibiotics Resistance and Antibiotics Usage) report – 2023 latest released 2. OECD report 3. ECDC report
Belgium	No specific binding legal mandate for AMR-related water. Monitoring in water is regionally implemented, guided by EU-level water and environmental directives	1. European Antimicrobial Resistance Surveillance Network (EARS-Net) 2. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 3. European Antimicrobial Resistance Surveillance network in Veterinary medicine (EARS-Vet) 4. EU One Health Action Plan against AMR	1. National Action Plan AMR 2020-2024 2. " SanitelMed " data collection system for antimicrobial use in animals, based on legal obligations at the veterinary level 3. BEAST Project v (Belgian Evaluation of Antimicrobial Stewardship Teams) 4. Surveillance Programs by Sciensano 5. Ongoing Development of New NAP AMR 2025-2029 6. IMHOTEP Project : Inventory of Hormonal and Organic Trace Matter in Heritage and Potable Waters	1. A 2023 study analysing recreational waters across Belgium found 24% of <i>E. coli</i> strains isolated from bathing sites resistant to at least one antibiotic, and 6% were multidrug-resistant. The Lesse river showed the highest levels of both absolute bacterial abundance and multidrug resistance (MAR index 0.063), with ESBL-producing <i>E. coli</i> present as well 2. The BELMAP report confirms robust national and regional AMR surveillance in humans and food animals, with MRSA prevalence falling but carbapenem-resistant <i>Klebsiella pneumoniae</i> and multidrug-resistant strains on the rise. 3. Belgium's hospitals largely follow EUCAST guidelines v for susceptibility testing 4. OECD report 5. ECDC report

1409

Country	National Obligation	EU Linkage	National Projects / Instruments	Additional References
Bulgaria	No specific binding legal mandate for AMR-related water.	<ol style="list-style-type: none"> 1. European Antimicrobial Resistance Surveillance Network (EARS-Net) 2. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 3. EU One Health Action Plan against AMR 	<ol style="list-style-type: none"> 1. APUA Bulgaria Action plan to combat antimicrobial resistance in Bulgaria (2020-2024) 2. The Bulgarian National Reference Laboratory (AMR NRL) has been upgrading capacity for AMR testing, including accreditation and molecular diagnostics 3. Research and participation in EFFORT project, sponsored by EC 2013-2018 	<ol style="list-style-type: none"> 1. A two-year monitoring study from 2015, examined water samples from the Dam of Iskar and the Black Sea coastal zone. While this study may not have employed advanced metagenomic techniques, it laid groundwork for understanding the presence of antibiotic-resistant bacteria in Bulgarian water bodies 2. A 2024 metagenomic study of the Iskar River—Bulgaria’s key freshwater resource—identified the presence of clinically relevant AMR genes (ARGs) such as carbapenemases (<i>blaOXA-58</i>, <i>blaIMP</i>) downstream of major wastewater treatment works (WWTPs), particularly after the Samokov plant. The study highlights anthropogenic impacts as a primary driver, with ARG levels typically rising closer to WWTP outlets 3. OECD report 4. ECDC report
Croatia	No specific binding legal mandate for AMR-related water. Institutions monitor environmental quality more generally but not specifically for AMR.	<ol style="list-style-type: none"> 1. European Antimicrobial Resistance Surveillance Network (EARS-Net) 2. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 3. European One Health Action Plan against AMR 4. NORMAN 5. AmReSu project 7. EU One Health Action Plan against AMR 	<ol style="list-style-type: none"> 1. National Control Program 2017-2021 2. The University Hospital for Infectious Diseases “Dr. Fran Mihaljevic” acts as Croatia’s AMR reference center, supported by a network of public health laboratories; 3. Laboratories submit isolate data to the reference center for national analysis and reporting 4. ARES project 	<ol style="list-style-type: none"> 1. Several Croatian universities and public health institutions have conducted targeted AMR research in wastewater and river systems, identifying the presence of resistance genes (e.g., <i>bla_TEM</i>, <i>bla_CTX-M</i>) and multidrug-resistant E. coli in hospital effluents and municipal WWTPs. Bacterial count as CFU per 100 mL of wastewater 2. Ongoing research projects such as the ARES project are examining groundwater sources used for public water supply. This project employs advanced culture-independent methods (high-throughput qPCR, 16S rRNA sequencing) and culture-dependent analyses of clinically important pathogens (e.g., <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Acinetobacter baumannii</i>) isolated from groundwater 3. OECD report 4. ECDC report

Country	National Obligation	EU Linkage	National Projects / Instruments	Additional References
Cyprus	No specific binding legal mandate for AMR-related water. The detection of AMR in environmental samples in Cyprus has been limited to academic and EU-funded projects, such as surveys of antibiotic-resistant bacteria in treated wastewater and coastal waters.	<ol style="list-style-type: none"> 1. European Antimicrobial Resistance Surveillance Network (EARS-Net) 2. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 3. Central Asian and European Surveillance of Antimicrobial Resistance (CAESAR) 4. European Union Reference Laboratory for Public Health on AMR (EURL-PH-AMR) 5. EU One Health Action Plan against AMR 	<ol style="list-style-type: none"> 1. National Action Plan (NAP) on AMR (2023–2027); 2. Cyprus, as a water-scarce country, has an advanced wastewater reuse system mainly for irrigation and groundwater enrichment. 	<ol style="list-style-type: none"> 1. Studies such as a 2020 investigation into treated effluent reuse for irrigation identified the presence of resistance genes (e.g., <i>sul1</i>, <i>qnrS</i>, <i>bla_TEM</i>) in samples from wastewater treatment plants 2. 2025 Danube Water Conference: Optimizing water reuse to address water scarcity in Cyprus 3. Community Antibiotic Consumption in Cyprus for the Period 2015 to 2022 4. OECD report 5. ECDC report
Czechia	No specific binding legal mandate for AMR-related water. The environmental AMR data in Czechia is gathered exclusively through academic or state-funded pilot studies, not through binding national legislation.	<ol style="list-style-type: none"> 1. NORMAN 2. AMR Watch project 3. European Antimicrobial Resistance Surveillance Network (EARS-Net) 4. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 5. Joint Programming Initiative on AMR (JPIAMR) 	<ol style="list-style-type: none"> 1. National Antibiotic Programme (NAP); 2. A National Reference Laboratory (NRL) for antibiotics leads surveillance activities and offers reference services, coordinating a network of local laboratories. 3. Ongoing development includes strategies extending toward 2030, addressing AMR in the aquatic environment and enhancing One Health approaches. 4. Additional initiatives include public projects like the Prevention of Antibiotic Resistance project, aimed at reducing antibiotic use in the population. 	<ol style="list-style-type: none"> 1. A 2022–2023 national study on surface waters and WWTP effluents in Czechia revealed that treated wastewater discharged into rivers contained <i>E. coli</i> isolates resistant to ampicillin, ciprofloxacin, gentamicin, and third- to fourth-generation cephalosporins. Many isolates were also ESBL-producers and carried class 1 integrons, indicating high potential for resistance gene transfer. 2. The issue of antimicrobial resistance in the aquatic environment of the Czech Republic 3. OECD report 4. ECDC report

1414

Country	National Obligation	EU Linkage	National Projects / Instruments	Additional References
Denmark	No specific binding legal mandate for AMR-related water. Efforts are part of research programs and sectoral stewardship initiatives.	<ol style="list-style-type: none"> 1. European Antimicrobial Resistance Surveillance Network (EARS-Net) 2. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 3. Joint Programming Initiative on AMR (JPIAMR) 4. World Health Organisations (WHO) programme for surveillance of antimicrobial consumption and resistance, GLASS 	<ol style="list-style-type: none"> 1. National Action Plan (June 2025) 2. Danish Integrated Antimicrobial Monitoring and Research Program - Antimicrobial Consumption and Resistance Surveillance Unit (DANMAP) 3. International Centre for Antimicrobial Resistance Solutions (ICARS) 	<ol style="list-style-type: none"> 1. Green Procurement Guidelines published by Amgros (a national pharmaceutical procurement agency) in 2023 require pharmaceutical companies to declare “environmentally harmful medicines”, including antibiotics 2. The Danish Environmental Protection Agency (EPA) funded a 2022 study showing the presence of sulfonamides, macrolides, and fluoroquinolones in effluent and surface waters 3. On July 3, 2025 the government has released a Guidance on water quality and supervision of water supply facilities 4. National initiatives use metagenomic surveillance of wastewater to monitor AMR trends. A study of Danish WWTPs reported AMR genes (ARGs) related to tetracycline, sulfonamide, and beta-lactam resistance found in influent and effluent waters 5. OECD report 6. ECDC report
Estonia	No specific binding legal mandate for AMR-related water.	<ol style="list-style-type: none"> 1. Joint Programming Initiative on AMR (JPIAMR) 2. European Joint Action on AMR (EU-JAMRAI) 3. NORMAN 	<ol style="list-style-type: none"> 1. AMR Management Strategy 2025–2030 	<ol style="list-style-type: none"> 1. Environmental surveillance of AMR in Estonia’s aquatic systems is currently limited but evolving. Regional data suggest that like other Baltic Sea region countries, Estonia’s aquatic environments may serve as hotspots for AMR gene dissemination due to human activity, though systematic studies remain limited 2. ECDC report 3. OECD report

1415

1416

Country	National Obligation	EU Linkage	National Projects / Instruments	Additional References
Finland	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> 1. European Antimicrobial Resistance Surveillance Network (EARS-Net) 2. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 	<ol style="list-style-type: none"> 1 National Action Plan 2024–2028 2. Finnish institutions such as the Finnish Institute for Health and Welfare (THL) and the Finnish Environment Institute (SYKE) are participating in projects like TruSTme (2023–2024), which explores wastewater treatment plants as real-time surveillance tools for AMR threat, including analysis of antibiotic resistance genes and microplastics in effluent 3. FINRES-Vet 	<ol style="list-style-type: none"> 1. A study found a high diversity of ARGs especially in non-disinfected systems; disinfected water systems had higher ratios of ARG reads relative to bacterial markers and elevated MRGs (mercury, arsenic resistance) suggesting selective pressures in treated waters. 2. Focus on pharmaceuticals in water 3. Finland has carried out hospital wastewater monitoring studies in Helsinki hospital effluents, weekly sampling detected and quantified multiple antibiotic resistance genes (ARGs), including carbapenem resistance genes blaGES, blaVIM, blaKPC, and others using HT-qPCR and digital platforms 4. University of Helsinki research on antimicrobial drugs repurposing 5. ECDC report 6. OECD report
France	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> 1. European Joint Action on AMR (EU-JAMRAI) 	<ol style="list-style-type: none"> 1. 2022-2025 National Strategy for Preventing Infections and Antibiotic Resistance 2. Interministerial Roadmap for 2024-2034 was published recently that sets a longer-term vision involving multiple ministerial plans in human and animal health sectors with 17 strategic objectives around awareness, research, surveillance, stewardship, innovation, and international cooperation 	<ol style="list-style-type: none"> 1. ANSES report on antibiotic resistance and antibiotics in the environment 2. Studies highlight hospital wastewater as a significant hotspot for AMR bacteria such as Pseudomonas, Acinetobacter, and Klebsiella pneumoniae, with ARGs being detected through municipal wastewater treatment stages, though advanced treatment like UV disinfection reduces final effluent contamination 5. ECDC report 6. OECD report

Country	National Obligation	EU Linkage	National Projects / Instruments	Additional References
Germany	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> 1. European Antimicrobial Resistance Surveillance Network (EARS-Net) 2. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 3. EU One Health Action Plan against AMR 	<ol style="list-style-type: none"> 1. "DART 2030" (German Antimicrobial Resistance Strategy) 2. SARA (Surveillance of Pathogens and Antibiotic Resistances in Aquatic Ecosystems) project 3. The RAaaO project (at TU Darmstadt testing ultrasound-ozonation combinations to reduce ARGs in wastewater treatment and evaluating molecular detection across resistance gene spectra) 	<ol style="list-style-type: none"> 1. National wastewater surveillance is undertaken by the <i>Robert Koch Institute (RKI)</i>, collaborating with the Umweltbundesamt and other federal and regional bodies. Ongoing monitoring includes antibiotic resistance genes (e.g., carbapenem-resistance in Enterobacterales) in sewage treatment plant effluents, using culture-based, digital PCR, and metagenomic methods 2. Study on fish resistomes and WWTP impacts 3. Holtemme river study 4. ECDC report 5. OECD report
Greece	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> 1. European Antimicrobial Resistance Surveillance Network (EARS-Net) 2. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 3. European Joint Action on AMR (EU-JAMRA!) 	<ol style="list-style-type: none"> 1. National Strategy for Quality of Care and Patient Safety for Greece 2025–2030 	<ol style="list-style-type: none"> 1. A 2023 four-year longitudinal study of a major WWTP in Northern Greece (Thessaloniki) found persistent levels of macrolides and fluoroquinolones (e.g. azithromycin, clarithromycin, ciprofloxacin) in influent and treated effluent. Concentrations rose during the COVID-19 pandemic and posed risks for AMR selection in receiving waters. 2. Environmental isolates of <i>Pseudomonas aeruginosa</i> collected from various Greek aquatic environments, rivers and coastal areas, included numerous ESBL-producers and isolates with class 1 integrons, indicating that Greek surface waters can host resistant strains 3. In Athens's Psytalia WWTP (serving ~4.6 million people), a 2025 study assessed the removal efficiency of both conventional activated sludge and nature-based treatment systems (e.g. constructed wetlands plus UV disinfection) for antibiotic-resistant bacteria (ARB) and resistance genes (ARGs). The findings highlight significant persistence of ARGs post-treatment 4. Research on antibiotic resistance in Lake Karla, Thessaly (2024) 5. Study on wastewater treatment challenges for ARG removal in Greece 6. ECDC report 7. OECD report

Country	National Obligation	EU Linkage	National Projects / Instruments	Additional References
Hungary	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> 1. European Antimicrobial Resistance Surveillance Network (EARS-Net) 2. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 3. EU One Health Action Plan against AMR 4. European Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI 2) 5. JPIAMR/OHAMR Research Roadmap 	National antimicrobial resistance (AMR) strategy is currently in development or draft form for the period 2025–2029	<ol style="list-style-type: none"> 1. A 2023 study reported high levels of pharmaceuticals including ibuprofen, naproxen, diclofenac, and carbamazepine in surface water of the Danube in Pest County. These compounds were detected despite standard water treatment, pointing to environmental persistence and potential AMR selection pressure 2. Shotgun metagenomic sequencing on untreated sewage from North Pest WWTP (Budapest) in 2016 found diverse antibiotic resistance genes (tetracycline, aminoglycoside, β-lactamase) overlapping with those found in animals and sludge, indicating environmental dissemination routes via wastewater and sludge reuse 3. Bibliometric analysis of antibiotic resistance in aquaculture emphasizing Hungary’s research contributions and trends 4. ECDC report 5. OECD report
Ireland	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> 1. European Antimicrobial Resistance Surveillance Network (EARS-Net) 2. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 3. JPIAMR/OHAMR Research Roadmap 4. European Joint Action on AMR (EU-JAMRAI) 	<ol style="list-style-type: none"> 1. National AMR Action Plan iNAP2 (2021–2025) 2. HSE Antimicrobial Resistance Infection Control (AMRIC) Action Plan 2022–2025 	<ol style="list-style-type: none"> 1. A 2023 study investigating public and private drinking water supplies in Ireland identified Enterobacterales including <i>E. coli</i>, <i>Serratia</i>, and <i>Enterobacter</i> with resistance to amoxicillin (~55%) and ciprofloxacin (<10%) highlighting potential AMR reservoirs in water supplies 2. Another investigation involving wastewater and surface water sampling between 2019 and 2020 identified 419 Enterobacterales isolates. Notably, 78% of water and 50% of sewage samples contained extended-spectrum beta-lactamase (ESBL) producers, with carbapenemase genes (e.g. bla_OXA-48, bla_NDM, bla_KPC) detected at multiple sites 3. The PIER (Public Health Impact of Exposure to Antibiotic Resistance in Recreational Waters) project and EPA-supported studies have highlighted the presence and persistence of AMR bacteria in recreational and drinking water, reinforcing the need for environmental AMR surveillance 4. ECDC report 5. OECD report

Country	National Obligation	EU Linkage	National Projects / Instruments	Additional References
Italy	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> 1. European Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI 2) 2. European Antimicrobial Resistance Surveillance Network (EARS-Net) 3. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 4. JPIAMR/OHAMR Research Roadmap 	<p>National Action Plan on Antimicrobial Resistance 2022–2025 (PNCAR)</p>	<ol style="list-style-type: none"> 1. A study monitoring wastewater treatment plants (WWTPs) in Sicily (Pantano D’Arce, Siracusa, Giarre) detected several ARGs such as blaSHV, erm(B), blaOXA, blaTEM, and blaCTX-M persistently in treated wastewater, indicating that aquatic systems serve as persistent AMR gene reservoirs potentially impacting public health 2. Large-scale aquatic AMR monitoring by Italian Military Navy (article) collecting aquatic AMR data across multiple marine and freshwater sites, contributing to a growing dataset on aquatic resistomes and the environmental prevalence of ARGs 3. ECDC report 4. OECD report
Latvia	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> 1. European Antimicrobial Resistance Surveillance Network (EARS-Net) 2. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 3. Transatlantic Taskforce on AMR (TATFAR) 4. European Joint Action on AMR (EU-JAMRAI) 5. JPIAMR/OHAMR Research Roadmap 	<ol style="list-style-type: none"> 1. One Health AMR Action Plan 2023-2027 2. LATOHOP’s (EC supported project) 	<ol style="list-style-type: none"> 1. Monitoring for bacteria in rivers, lakes and ponds was conducted in 2001 and 2002 but there is no data available on further analyses 2. ECDC report 3. OECD report

1421

1422

1423

Country	National Obligation	EU Linkage	National Projects / Instruments	Additional References
Lithuania	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> 1. European Antimicrobial Resistance Surveillance Network (EARS-Net) 2. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 3. EU One Health Action Plan against AMR 4. Transatlantic Taskforce on AMR (TATFAR) 5. European Joint Action on AMR (EU-JAMRAI) 6. JPIAMR/OHAMR Research Roadmap 	National Action Plan on Antimicrobial Resistance (PNCAR)	<ol style="list-style-type: none"> 1. Lithuania has conducted studies on the microbiome and resistome dynamics across a salinity gradient, analysing water and sediment samples from the Baltic Sea coast and the Curonian Lagoon between 2017 and 2023. These studies aimed to examine the microbiome and resistome dynamics, providing insights into the diversity of antibiotic resistance genes in aquatic environments 2. ECDC report 3. OECD report
Luxembourg	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> 1. European Antimicrobial Resistance Surveillance Network (EARS-Net) 2. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 3. EU One Health Action Plan against AMR 4. Transatlantic Taskforce on AMR (TATFAR) 5. European Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI 2) 6. JPIAMR/OHAMR Research Roadmap 7. Transatlantic Taskforce on AMR (TATFAR) 	National Action Plan on Antimicrobial Resistance (PNCAR) 2018-2022 which was extended until 2024. Concrete details on a 2025 extension or the launch of a new national plan for 2025 onwards remain unavailable as of now	<ol style="list-style-type: none"> 1. Luxembourg has been involved in research projects studying the prevalence and spread of antimicrobial resistance, including the monitoring of antibiotic-resistant bacteria in various environments. These studies contribute to understanding the scope of AMR but are not part of a legally mandated surveillance system 2. In 2024, Luxembourg hosted the 2nd WES-LUXEMBOURG DAY, focusing on the growing challenge of antimicrobial resistance (AMR). The event showcased how wastewater and environmental surveillance can help detect and track resistance genes and resistant pathogens at both national and European levels 3. ECDC report 4. OECD report

1424

1425

Country	National Obligation	EU Linkage	National Projects / Instruments	Additional References
Malta	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> 1. European Antimicrobial Resistance Surveillance Network (EARS-Net) 2. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 3. EU One Health Action Plan against AMR 4. Transatlantic Taskforce on AMR (TATFAR) 5. European Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI 2) 6. JPIAMR/OHAMR Research Roadmap 7. Transatlantic Taskforce on AMR (TATFAR) 	<ol style="list-style-type: none"> 1. National Strategy & Action Plan for the Prevention and Containment of Antimicrobial Resistance (2020–2028). The Strategy will be regularly reviewed and updated so that it remains reflective of the work that is underway, and action plans for the future. The review Dates are set for 2023 and 2026; 2. WHO-documented national AMR strategy covering 2020–2028 	<ol style="list-style-type: none"> 1. Addressing AMR in Malta, National AMR Committee presentation 2. ECDC report 3. OECD report
The Netherlands	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> 1. European Antimicrobial Resistance Surveillance Network (EARS-Net) 2. European Surveillance of Antimicrobial Consumption Network (ESAC-Net) 3. EU One Health Action Plan against AMR 4. European Joint Action on AMR (EU-JAMRAI) 5. JPIAMR/OHAMR Research Roadmap 	<ol style="list-style-type: none"> 1. National Action Plan on Antimicrobial Resistance (AMR) for 2024–2030 2. “Chain Approach” (2016 – ongoing) 3. AMR3 (2022–2025) 	<ol style="list-style-type: none"> 1. Continuous monitoring and reporting of antibiotic use and resistance trends in humans and animals through the annual NethMap/MARAN report (2024) 2. The Dutch chain approach on pharmaceuticals in water: Stakeholders acting together to reduce the environmental impact of pharmaceuticals 3. ECDC report 4. OECD report

1426

Country	National Obligation	EU Linkage	National Projects / Instruments	Additional References
Poland	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> JPIAMR/OHAMR Research Roadmap EU One Health Action Plan against AMR 	<ol style="list-style-type: none"> National Health Programme 2021–2025; BINWIT platform at the Polish Academy of Sciences, enhancing access to scientific resources relevant to bacteriophages and immunology 	<p>A 2020 study found that ~70% of monitored antimicrobial agents including ciprofloxacin, macrolides, and sulfamethoxazole were present in influent and effluent of two Polish wastewater treatment plants. The concentrations posed medium to high risk for resistance selection in receiving rivers, even after conventional treatment (~50% removal efficacy)</p> <ol style="list-style-type: none"> A 2020 study identified antibiotic resistance genes (ARGs) in wastewater systems, including hospital effluents, underscoring the dissemination of resistant determinants via treatment facilities A research conducted in Oder river water shows microplastic particles in water environments may serve as vectors for dispersing pathogens and ARGs Recent Polish study on AMR in recreational lakes (2025) Study on microbial shifts post-flooding in Wrocław (2025) ECDC report OECD report
Portugal	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> European Antimicrobial Resistance Surveillance Network (EARS-Net) European Surveillance of Antimicrobial Consumption Network (ESAC-Net) EU One Health Action Plan against AMR JPIAMR/OHAMR Research Roadmap 	<ol style="list-style-type: none"> National plan on AMR covers the period around 2019–2023/24, with ongoing engagement and updates to align with EU and WHO guidelines "Drive-AMS" training course, which by early 2025 had expanded to involve sixteen national hospitals aiming to improve antibiotic prescription practices and reduce antibiotic-resistant bacteria emergence 	<ol style="list-style-type: none"> A 2025 study analysing environmental samples from 65 sheep and goat farms in central Portugal, detected antimicrobial resistance genes (ARGs) associated with multiple antibiotic classes including β-lactams, tetracyclines, macrolides, and sulfonamides in water, soil, pasture, and bedding. ARGs were found in 83% of samples, many exhibiting multidrug resistance potential ECDC report OECD report

Country	National Obligation	EU Linkage	National Projects / Instruments	Additional References
Romania	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> EU One Health Action Plan against AMR JPIAMR/OHAMR Research Roadmap 	<ol style="list-style-type: none"> National Recovery and Resilience Plan (NRRP) Romania and Norway collaborate against Antibiotic Resistance 	<ol style="list-style-type: none"> A 2024 study assessed antibiotic residues and microbial loads in three Romanian wastewater treatment plants (WWTPs) between 2021 and 2022. It documented persistent antibiotics including amoxicillin and clarithromycin in effluent waters, posing medium to high environmental risk and potential for resistance selection even after treatment. Comprehensive one Health-oriented research highlights the presence and transmission of resistant bacterial strains and antibiotic resistance genes (ARGs) in wastewater influent and effluent. For example, <i>Klebsiella pneumoniae</i> ST101, including carbapenem-resistant isolates, was detected throughout two Romanian hospitals co-presenting resistance and heteroresistance to colistin. Study of Romania’s high antibiotic use and AMR challenges (2025). Qualitative study on antibiotic treatment and prevention challenges in Romania (2024) Recent Romanian research on Enterobacterales and AMR in Aquatic Environments (2025) Review on Heavy Metals and Microplastics Impacting AMR in Aquatic Systems ECDC report OECD report
Slovakia	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> EU One Health Action Plan against AMR JPIAMR/OHAMR Research Roadmap European Antimicrobial Resistance Surveillance Network (EARS-Net) 	National Action Plan on Antimicrobial Resistance for the period 2019–2021; formally published distinct national plan explicitly titled for the year 2025 is not clearly documented in available public sources.	<ol style="list-style-type: none"> A pilot study conducted at two wastewater treatment plants in Bratislava and Košice measured concentrations of 33 antibiotics, including ciprofloxacin and clarithromycin, in influent and effluent. Removal efficiencies were insufficient, and resistant fecal coliforms were also detected in sludge. Sub-inhibitory antibiotic levels create selective pressure for resistance development. A 2023 study of <i>Acinetobacter</i> spp. in the WWTP at Kokšov-Bakša (Košice) identified genetically diverse, antibiotic-resistant strains—indicating the plant as a potential environmental reservoir and contributor to AMR spread in receiving waters. Another year-long study in Petržalka WWTP (Bratislava) documented multidrug-resistant coliforms and enterococci in both influent and effluent, including <i>E. coli</i> and <i>Morganella morganii</i>. ECDC report OECD report

Country	National Obligation	EU Linkage	National Projects / Instruments	Additional References
Slovenia	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> EU One Health Action Plan against AMR JPIAMR/OHAMR Research Roadmap EU JAMRAI 2 - JAZMP 	Current national strategy covers 2019–2024, with a draft for the new National "One Health" AMR Strategy planned for 2025–2030	<ol style="list-style-type: none"> A pilot study in Slovenia (2007) investigated removal of pharmaceutical residues including ibuprofen, diclofenac, ketoprofen in a pilot wastewater treatment plant. The study showed variable removal efficiencies, with certain compounds persisting post-treatment, highlighting the limitations of conventional WWTPs in eliminating pharmaceutical pollutants Slovenia's Waters Act was amended in 2021, but the amendment was overwhelmingly rejected via referendum due to concerns about weakening water protection. There is no national legislation mandating AMR or antibiotic residue monitoring in surface or wastewater ECDC report OECD report
Spain	No specific binding legal mandate for AMR-related water	<ol style="list-style-type: none"> EU One Health Action Plan against AMR JPIAMR/OHAMR Research Roadmap European Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI 2) 	Spain's national strategy on antimicrobial resistance (AMR) for 2025 is framed within the ongoing Spanish National Action Plan against AMR (PRAN), which was originally launched in 2014. The existing Water Law (Ley de Aguas, 1985) delegates water quality regulation to basin agencies but does not require AMR or antibiotic residue monitoring.	<ol style="list-style-type: none"> PRAN coordinated by AEMPS and MITECO in collaboration with IDAEA-CSIC, published a Report 2.2 (2024) monitoring five antibiotics including erythromycin, clarithromycin, azithromycin, ciprofloxacin, and amoxicillin in 16 WWTPs and associated rivers. Elevated residues were found throughout, confirming environmental exposure and potential risk for AMR selection. A recent study (2024) assessed pharmaceutical residues in Catalonia's main rivers (Llobregat and Besòs), analysing 78 pharmaceuticals using LC–MS/MS. Detectable levels of ciprofloxacin, macrolides, NSAIDs, and others were found, highlighting pharmaceutical contamination hotspots in surface waters. A 2023 urban study from Northern Spain measured culturable antibiotic-resistant bacteria (ARB) and antibiotic resistance genes (ARGs) in influent and effluent of two WWTPs. Findings included ESBL-producing <i>E. coli</i> and diverse ARGs persisting after treatment suggesting WWTP effluents as ongoing sources of AMR dissemination. A pilot study in Castellón used wastewater-based epidemiology (WBE) during 2021–22 to quantify 11 antibiotics and multiple ARGs concurrently; azithromycin and ciprofloxacin were prevalent, with strong correlations observed between overall antibiotic load and the int11 resistance gene Recent review on micromotor nanotechnology for AMR remediation in Spanish water environments (2025) Seasonal ARG and antibiotic residue study in Spanish Mediterranean waters

Country	National Obligation	EU Linkage	National Projects / Instruments	Additional References
				7. ECDC report 8. OECD report

1429

Country	National Obligation	EU Linkage	National Projects / Instruments	Additional References
Sweden	Binding legal requirement (Water Management Ordinance HVMFS 2019:25)	1. EU One Health Action Plan against AMR 2. JPIAMR/OHAMR Research Roadmap 3. European Antimicrobial Resistance Surveillance Network (EARS-Net)	1. Swedish Strategy to Combat Antibiotic Resistance was adopted in February 2020 and extended in November 2023 to run until the end of 2025; 2. CARE - Centre for Antibiotic Resistance Research in Gothenburg is a collaborative and interdisciplinary research centre at the University of Gothenburg and Chalmers University of Technology that conducts research into the environmental dimensions of antibiotic resistance 3. SLU Future One Health (slu.se) platform for interdisciplinary research and collaborations that provides knowledge and solutions to good in sustainable ecosystems 4. STRAMA , the strategic program against antibiotic resistance, which provides education and monitors resistance trends	1. National Environmental Quality Standards (EQS) for certain antibiotics such as ciprofloxacin (0.1 µg/L, MAC-EQS) classified as river basin-specific pollutant; AMR relevance explicitly acknowledged 2. A strong cross-sectoral national collaborative function led jointly by the Public Health Agency of Sweden and the Swedish Board of Agriculture, which engages 21 government agencies and 5 organizations to ensure a coordinated response across sectors 3. Antibiotic Smart Sweden's Criteria for Municipal Wastewater 4. The Swedish experience - a summary on the Swedish efforts towards a low and prudent use of antibiotics in animal production (In 1986, Sweden, as the first country in the world banned all use of antibiotics as growth promoters in food animal production) 5. Sweden's successful approach to antibiotic resistance can be used as inspiration in other countries – 2023 – ReAct 6. ECDC report 7. OECD report

1430 *Source: JRC*

1431 **Note on the source:**

1432 European Environmental Agency. Urban Waste Water Treatment Directive, Treatment plants reported under UWWTD data call 2021 - PUBLIC
1433 VERSION, Jan. 2023.

1434 UWWTD Treatment Plants, Jan. 2023 is one of the datasets produced within the frame of the reporting under 12th UWWTD Art.15 reporting
1435 period (UWWTD data call 2021). The Urban Waste Water Treatment Directive (UWWTD) (91/271/EEC) obliges Member States to report data
1436 on the implementation of the Directive upon request from the European Commission bi-annually. Reported data include receiving areas as
1437 designated under UWWTD, agglomerations, urban wastewater treatment plants serving the agglomerations and points of discharges.
1438 Dataset UWWTD Treatment Plants contains urban wastewater treatment plants and collecting systems without UWWTP, including their
1439 coordinates, capacity and actual load treated, type of treatment and data on the performance of plants. This dataset includes the reported
1440 treatment plants displayed on the UWWTD maps (<https://www.eea.europa.eu/themes/water/european-waters/water-use-and-environmental-pressures/uwwtd/interactive-maps/urban-waste-water-treatment-maps-3>).

1442 The active and connected treatment plants with correct coordinates in the reported data were selected from the source European UWWTD
1443 tabular dataset which is available on the download link <https://www.eea.europa.eu/data-and-maps/data/waterbase-uwwtd-urban-waste-water-treatment-directive-9>. The definition of the UWWTD Treatment Plants dataset attributes (fields) is available on the link: The full
1444 dataset, including non active and non connected treatment plants are available under "Urban Waste Water Treatment Directive, Treatment
1445 plants reported under UWWTD data call 2022 - INTERNAL VERSION, Jan. 2023" (<https://sdi.eea.europa.eu/catalogue/inspire-pds/eng/catalog.search#/metadata/0d0c9029-735e-4968-a577-9c22fcf7b2b0>). The published output contains data reported in 2022.
1446 Current output is provisional, as it is subject to the Commission's compliance check, following which some records may be amended, and
1447 further information will be added.
1448
1449

1450 **Annex 5: Cost estimation and evaluation for monitoring AMR in wastewater**

1451 **Sampling**

1452 Monitoring AMR in WWTPs is typically conducted at the plant's inlet and outlet. This process is often
 1453 integrated with existing sampling activities aimed at process control or compliance checks, which
 1454 assess various biological and chemical parameters such as chemical pollutants, *E. coli*, and other
 1455 pathogens. To capture the dynamics of AMR effectively and avoid missing peak occurrences, it is
 1456 advisable to use time or flow-integrated sampling methods. These methods involve collecting
 1457 representative samples over a period or based on flow volume, and they benefit from the efficiency
 1458 and consistency provided by automated equipment. Larger WWTPs often already utilise such
 1459 equipment, so the cost estimates provided below should be considered in the context of implementing
 1460 a new automated system, rather than the significantly lower cost of incorporating additional sampling
 1461 into an existing workflow.

1462 **Table A5.** Cost overview for sampling equipment needed for AMR monitoring. The figures are based on actual
 1463 offers (year of reference 2024) and JRC based experiences

Cost type	Cost for	Description	Estimate
Capital costs	Automated Sampling Equipment	Sampler Purchase depending on features such as refrigeration, portability, and data logging capabilities	€3,000 to €10,000
		Auxiliary Equipment Includes items like flow meters and additional infrastructure or mounting apparatus	€1,000 to €5,000,
Operating costs	Maintenance and Calibration	Regular Maintenance: Routine checks and servicing to ensure equipment accuracy and longevity	€500 to €1,000 per year
		Calibration: Accurate measurement requires periodic calibration, typically annually	€100 to €300
	Consumables	Bottles and Tubing: Replacement of sampling bottles and tubing due to wear or contamination	€200 to €500 annually.
		If samples require preservation for later analysis, chemicals might add a minor expense	€50-€200 per year
	Data Management and Connectivity	Software and Subscription Systems: Some automated samplers offer data logging or remote connectivity features that might require software licenses or subscriptions	€100 to €500 annually.
Labor Costs	Setup and Operation	Installation Labor: Setting up the system involves initial installation	€500 to €2,000 for contractor services, plus training.
		Ongoing Monitoring: Personnel time for monitoring equipment performance, resolving issues, and retrieving samples	€1,000 to €3,000 annually depending on the frequency of sample collection and analysis

1464 *Source: EC-JRC*

1465 **Cost for PCR measurements**

1466 **a) 'Conventional' quantitative PCR (qPCR)**

1467 The cost of a qPCR test for AMR can vary widely depending on several factors, including whether it's
1468 performed in-house or sent to an external lab, the specific genes being targeted, and the number of
1469 samples. Generally, costs range from around 50 to 1000 Euro per test. To illustrate, in-house testing
1470 using a kit like the LuminUltra GeneCount® Q-16 qPCR system, the cost can be as low as 42 Euro per
1471 test, while sending samples to an external lab can cost between 300 and 1,000 Euro per test. Specific
1472 kits such as for instance AMR1 multiplexed qPCR assay bundles from pcrassays.com can cost around
1473 550,000 Euro. The complexity of the assay, the number of genes being targeted, and the type of
1474 reagents used can all influence the final cost. In addition to the direct testing cost, it's important to
1475 consider the cost of specialised equipment like qPCR machines, which can range from hundreds of
1476 thousands to millions of dollars for cutting-edge last generation technology.

1477 Hence, estimating the cost of qPCR test for ARGs in wastewater is complex and involves considering
1478 various factors including reagents, equipment, labour, and overhead (Table A6). In the following is a
1479 breakdown based on JRC internal experiences and recently collect quotations in the context of the so-
1480 called European Super-Sites Sentinel System for Wastewater.

1481 Given these factors, the total cost for processing a single sample through qPCR for AMR/ARGs in
1482 wastewater can vary significantly, typically ranging from 50 to 400 Euro per sample depending on
1483 economies of scale, location, and institutional pricing agreements. For a more precise estimate, each
1484 component would need to be itemised and adjusted based on specific laboratory settings, sample
1485 throughput, and geographic considerations.

1486 **Table A6.** Cost overview for AMR monitoring by qPCR. The figures are based on actual offers (year of reference
 1487 2024) and JRC based experiences

Cost type	Cost for	Description	Estimate
Material and Equipment	Reagents and Consumables	Custom primers and probes specific to the AMR/ARG targets depending on the complexity and supplier	€100 to €500 per assay
		high-quality q-PCR master mix	€1 to €5 per reaction
		The consumables for running reactions, including plates and seals	€0.50 to €1 per reaction
		Nucleic Acid Extraction Kits depending on the kit's efficiency and supplier	from €2 to €10
	Equipment	qPCR Machine depending on its capacity and features. The depreciation costs over several years can be factored into the cost per test.	€10,000 to €100,000
	Miscellaneous Lab Equipment	Include costs for centrifuges, pipettes, and other necessary equipment, though these are not typically broken down per test	
Labour	Sample Collection and Processing	Personnel costs for collecting samples and preparing depending on location and expertise	€20 to €50 per hour of labour
		Running and analysing qPCR involves setting up the reactions, running the qPCR, and analysing the data	1-3 hours of skilled labour
Overhead and Indirect Costs	Facility Costs	Rental, utility, and maintenance costs for the laboratory space	<i>Not quantified</i>
	Quality Control and Reporting	Includes expenses related to ensuring reliability of results and preparing reports.	<i>Not quantified</i>
Additional Costs	Research and Development	If the assay requires the development of new primers/probes or testing protocols.	<i>Not quantified</i>
	Compliance and Accreditation	Adhering to regulatory standards may incur additional costs	<i>Not quantified</i>

1488 *Source: EC-JRC*

1489 **b) Digital droplet PCR (ddPCR) cost evaluation**

1490 ddPCR is an advanced nucleic acid detection method that offers greater precision and sensitivity
 1491 compared to quantitative PCR (qPCR). Unlike qPCR, which monitors DNA amplification in real-time to
 1492 quantify DNA based on the fluorescence emitted throughout the reaction and typically requires a
 1493 standard curve for absolute quantification, ddPCR partitions the sample into thousands of nanolitre-
 1494 sized droplets, conducting PCR in each droplet. This partitioning allows for absolute quantification by
 1495 directly counting the proportion of droplets containing the target DNA, eliminating the need for a
 1496 standard curve and offering excellent resistance to sample inhibitors. This makes ddPCR especially
 1497 suitable for detecting low-abundance targets, such as rare alleles, low-level viral loads, and minimal
 1498 residual disease in cancer monitoring, providing a high level of precision that is crucial in clinical
 1499 diagnostics and cutting-edge research. However, ddPCR is generally lower in throughput compared to
 1500 qPCR and is generally more expensive than qPCR due to several factors. First, ddPCR requires
 1501 specialised equipment for droplet generation and partitioning, which tends to have a higher initial cost
 1502 compared to standard qPCR machines. Additionally, the consumables for ddPCR, including reagents
 1503 and droplet generation materials, can be more costly. This results in a higher per-reaction cost for
 1504 ddPCR compared to qPCR. While ddPCR offers superior sensitivity and precision, especially for
 1505 detecting low-abundance targets or rare mutations, the increased cost may be a consideration for
 1506 large-scale studies or routine analyses where the enhanced sensitivity of ddPCR is not necessary.

1507 Despite these higher costs, the benefits of ddPCR in terms of accuracy and robustness against inhibitors
 1508 may justify the expense in clinical diagnostics and specialised research applications. A more detailed
 1509 cost-breakdown is displayed in the table below.

1510 **Table A7.** Cost overview for AMR monitoring by ddPCR. The figures are based on actual offers (year of
 1511 reference 2024) and JRC based experiences

Cost type	Cost for	Description	Estimate
Material and Equipment	Reagents and Consumables	Custom primers and probes specific to the AMR/ARG targets depending on the complexity and supplier. Similar to qPCR, but the specific reagents for partitioning and droplet generation can be more expensive.	€100 to €500 per assay
		Droplet Generation and Master Mixes	€5 to €10 per reaction
		The consumables for running reactions, including plates and seals, etc.	€2.50 to €10 per reaction
	Equipment	ddPCR Machine depending on its capacity and features. The depreciation costs over several years can be factored into the cost per test.	€50,000 to €200,000
	Miscellaneous Lab Equipment	Include costs for centrifuges, pipettes, and other necessary equipment, though these are not typically broken down per test	
Labor	Sample Collection and Processing	Personnel costs for collecting samples and preparing depending on location and expertise	€20 to €50 per hour of labour
		Running and analysing ddPCR involves setting up the reactions, running the qPCR, and analysing the data	1-3 hours of skilled labour
Overall costs		Cost per ddPCR test for AMR/ARGs	€100 - €400

1512 *Source: EC-JRC*

1513 **c) Cultivation-based PCR cost evaluation**

1514 Cultivation-based PCR, unlike standard PCR, begins with an initial step where microorganisms are
 1515 grown in specific culture media before PCR amplification. While this process aims to enrich and isolate
 1516 viable organisms for analysis, confirming microbial viability and providing insights into active
 1517 populations, it has notable drawbacks. The method is significantly more time-intensive and resource-
 1518 demanding due to its reliance on incubation periods and specific growth conditions, leading to slower
 1519 results compared to the rapid efficiency of qPCR. Additionally, cultivation-based PCR can introduce
 1520 bias, as some microorganisms do not grow well in laboratory settings, potentially skewing results and
 1521 underrepresenting certain species. In contrast, qPCR bypasses these limitations by quickly detecting
 1522 genetic material from both viable and non-viable organisms, offering more comprehensive and timely
 1523 data. For many applications, especially those requiring high throughput and quick turnaround, qPCR is
 1524 favoured due to its speed, lower cost, and the ability to provide immediate insights without the
 1525 prolonged and selective steps inherent in cultivation-based methods. A6 gives an overview on the costs
 1526 for cultivation-based PCR Methods.

1527 **Table A8.** Cost overview for AMR monitoring by cultivation-based PCR. The figures are based on actual offers
 1528 (year of reference 2024) and JRC based experiences

Cost type	Cost for	Description	Estimate
Direct costs	Culture Media and Materials	The cultivation step requires media, cost of which depends on the organism and media complexity.	€1 to €5 per assay
		Cultivation Time and Space. Considerations include incubator use and lab space, adding a cost per sample due to time and resource allocation	€5 to €10 per reaction
Follow-up costs¹	Reagents and Consumables	for the DNA extraction and amplification steps	€5 to €15 per sample
Labour	Extended Time for Growth	Cultivation significantly extends the timeline for obtaining results, impacting labour costs, depending on the duration and complexity of thorough microbial culturing.	€50 to €100
Overall costs		Cost per Cultivation-based PCR test for AMR/ARGs	€100 - €300

1529 ¹ for equipment etc. see Table A5

1530 *Source: EC-JRC*

1531 **d) Costs for metagenomics**

1532 Conducting a cost evaluation for metagenomics specifically targeting AMR/ARGs involves multiple
 1533 components that contribute to the overall expense. Below is a breakdown similar to what was used
 1534 for qPCR but adapting to the unique requirements of metagenomic analysis.

1535 **Table A9.** Cost overview for AMR monitoring by metagenomics. The figures are based on actual offers (year of
 1536 reference 2024) and JRC based experiences

Cost type	Cost for	Description	Estimate
Sample collection and preparation	Collection and Storage	Similar to other methods, for collection and cold transport.	€5 to €20 per sample
	DNA Extraction	High-quality extraction kits or automated systems are crucial for metagenomics	€5 to €20 per sample
Library Preparation	Kits and Reagents	Preparing DNA libraries for sequencing is a significant cost, depending on the kit and protocol used	€50 to €150 per sample
Sequencing cost	Platform and Throughput	Costs vary based on the chosen sequencing platform (e.g., Illumina, Oxford Nanopore) and the depth of sequencing required. Costs depend on the desired coverage and data output.	€100 and €1,000 per sample. Higher costs are possible.
Bioinformatics Analysis	Hardware and Software	Initial setup might involve costs for computational hardware or cloud resources, alongside software licenses or subscriptions for specialised analysis tools.	€50 to €300 per analysis
	Expert Analysis	Interpretation of metagenomic data requires specialised bioinformatic expertise, costs depending on complexity and depth of analysis.	€100 to €300 per sample
Overhead and Indirect Costs	Personnel and Training	Skilled personnel are needed to manage and conduct metagenomic workflows	€200 to €500 per project
	Facility and Equipment Maintenance	Includes depreciation and maintenance of sequencing equipment and laboratory facilities.	Not quantified
Overall costs	Per Sample Costs	Cost per metagenomics for AMR/ARGs	€400 - €3500
	Economies of Scale	Larger batch sizes can reduce costs per sample due to more efficient use of sequencing platforms and shared bioinformatics resources.	

1537 *Source: EC-JRC*

1538 Metagenomics stands out for its agnostic approach to sequencing, offering unparalleled value in the
1539 study of AMR and ARGs Unlike targeted methods such as qPCR, which require prior knowledge of
1540 specific genes, metagenomics allows for the comprehensive profiling of entire microbial communities.
1541 This means that all genetic material present in a sample is sequenced and analysed, making it possible
1542 to capture the full resistome, including known and previously unidentified resistance genes. This
1543 holistic perspective is crucial for understanding the complexity and dynamics of resistance in diverse
1544 environments, especially in settings where unknown or emerging resistance mechanisms may be
1545 present.

1546 Indeed, one of the most significant advantages of metagenomics is its ability to create a digitalised
1547 snapshot, or "memory," of the genetic content within a sample. The data generated acts not only as a
1548 current analytical tool but also as a rich resource that can be revisited as new insights or technologies
1549 emerge. This allows researchers to re-analyse the sequenced data at a later stage, making
1550 metagenomics a forward-thinking investment that can adapt to future scientific questions. For
1551 instance, if new ARGs are discovered or if there are advancements in bioinformatics, existing
1552 metagenomic datasets can be re-mined for additional insights, providing immense long-term value.

1553 This ability to store and re-assess data enhances the strategic importance of metagenomics, justifying
1554 its higher initial costs. While it is significantly more expensive than qPCR, metagenomics provides depth
1555 and breadth that are unmatched by more targeted methods. For decision-makers, the choice between
1556 qPCR and metagenomics should weigh the study's objectives, budget constraints, and the potential
1557 need for comprehensive or retrospective analyses. For routine surveillance or studies focusing on
1558 specific genes, qPCR's cost-effectiveness and speed make it an attractive choice. However, in research
1559 that requires expansive data collection, the identification of novel resistance genes, or when dealing
1560 with complex, multi-pathogen communities, metagenomics offers unparalleled insight, making it a
1561 valuable tool despite its higher cost.

1562 **Emerging technologies: Lab-on-a-Chip and Smart-Chips**

1563 The field of AMR monitoring is witnessing a technological evolution with the introduction of innovative
1564 platforms such as lab-on-a-chip sensors and Smart-Chip technologies. These cutting-edge solutions
1565 offer the promise of transforming AMR surveillance through a decentralised and cost-effective
1566 approach.

1567 These emerging technologies, now entering increasingly also the European market, promise to
1568 democratise access to AMR monitoring, enabling widespread adoption in various geographic and
1569 resource settings. They are particularly advantageous for remote or under-resourced locations, where
1570 traditional laboratory setups may be impractical. By facilitating quick, on-site AMR detection, these
1571 devices can enhance decision-making processes for patient treatment or environmental intervention,
1572 potentially improving health outcomes and reducing the spread of resistance.

1573 Despite their potential, lab-on-a-chip and smart-chip technologies are at an early stage of market
1574 deployment. There are challenges related to mass manufacturing, device standardisation, and the
1575 robustness of sensors, which must be addressed to ensure reliability and consistent performance.
1576 While these devices can generate large volumes of data, integrating this information into existing
1577 health and environmental data systems remains a challenge. Effective data handling, storage, and
1578 interpretation infrastructure need to be established. Ensuring these technologies meet stringent

1579 regulatory standards for diagnostic accuracy and reliability is crucial for widespread adoption,
1580 particularly in clinical settings.

1581 **a) Lab-on-a-Chip sensors:**

1582 These microfluidic devices integrate multiple laboratory functions onto a single chip, capable of
1583 handling small fluid volumes. They can efficiently perform sample preparation, DNA amplification, and
1584 detection of AMR genes, effectively miniaturising and automating complex laboratory processes. By
1585 reducing the need for bulky equipment and labour-intensive procedures, lab-on-a-chip devices
1586 significantly cut down costs associated with traditional AMR detection methods. They enable rapid,
1587 point-of-care testing, which can be particularly beneficial in settings lacking extensive laboratory
1588 infrastructure.

1589 **b) Smart-Chip technologies:**

1590 Smart-Chips incorporate advanced biosensors and electronic components, potentially allowing real-
1591 time data monitoring and transmission. This makes them suitable for continuous monitoring
1592 applications, where data can be instantly analysed and shared via digital networks. These chips
1593 facilitate a shift towards more localised monitoring of AMR, improving responsiveness and enabling
1594 targeted interventions in both healthcare and environmental contexts. Their deployment could
1595 significantly reduce sample transport and processing costs.

1596 **Cost comparison and potential savings**

1597 When comparing the potential costs of emerging technologies like lab-on-a-chip sensors and smart-
1598 chip platforms to a traditional PCR cost of approximately 250 Euro per sample, these innovative
1599 platforms can offer significant savings over time.

1600 Initially, Lab-on-a-Chip and Smart-Chip Per-Test Costs per test using might be somewhat comparable
1601 to or slightly less than traditional PCR, possibly ranging from 50 to 150 Euro per test depending on the
1602 complexity of the test and initial deployment costs. As production scales up and technology advances,
1603 costs could potentially fall below 50 Euro per test.

1604 As these technologies mature and manufacturing scales up, the cost per test is likely to decrease
1605 significantly. Mass production can dramatically lower the cost of materials and components, pushing
1606 costs well below traditional PCR estimates. By providing on-site, rapid testing and reducing logistics
1607 and processing times associated with centralised laboratories, these technologies can cut down
1608 operational costs related to sample transport, handling, and lab personnel. Once deployed, the
1609 automated nature of these devices minimises the need for extensive laboratory infrastructure and
1610 manpower, potentially leading to lower operational expenses over time. The potential to reconfigure
1611 and update these devices for new tests without high additional costs further enhances their cost-
1612 effectiveness, offering continual savings compared to re-developing specific PCR tests.

1613 While initial costs for deploying lab-on-a-chip sensors and smart-chip technologies may be higher or
1614 comparable to traditional PCR testing, they hold the potential to significantly reduce per-sample costs
1615 in the long run. With costs that could eventually fall well below 50 Euro per test as the technology
1616 matures, these innovations promise substantial savings. This potential reduction in cost aligns with a
1617 decentralised and efficient approach to AMR monitoring, especially as the market and technology
1618 evolve.

1619 The emergence of lab-on-a-chip sensors and smart-chips marks a pivotal shift towards more accessible,
1620 efficient, and potentially low-cost AMR monitoring. While these technologies hold significant promise,

1621 ongoing advancements and overcoming current limitations will be essential to fully realise their
1622 potential and enhance the global capacity to monitor and respond to antimicrobial resistance
1623 effectively. Their integration could complement existing technologies like qPCR and metagenomics,
1624 providing a comprehensive suite of tools to tackle AMR on multiple fronts.

1625 **Market insights from public procurement**

1626 In 2024, the European Commission's HaDEA published a EU4Health call for tenders
1627 HADEA/2024/OP/0017 - Framework contracts to provide services and supplies to measure pathogens
1628 and pollutants of emerging concern in untreated wastewater samples as part of a global sentinel
1629 system.

1630 This call aimed at purchasing supplies and equipment for wastewater sampling and testing, and
1631 services to measure pathogens and pollutants of emerging concern in untreated wastewater samples
1632 at strategic locations known as super-sites. These super-sites will constitute a sentinel system which
1633 will be part of the global sentinel system that will ensure exchange of data to establish an early warning
1634 system for future pandemics. In this context, price information for measurements of pathogens by
1635 PCR, WGS/NGS measurements and Shotgun Metagenomics in untreated wastewater samples were
1636 obtained. The information collected allowed a comprehensive assessment of market prices for some
1637 AMR/ARG targets and was further confirmed by own surveys and tenders performed by the JRC.

1638 The observed and document price range for the measurement of azole resistant *Aspergillus fumigatus*,
1639 Carbapenem-/colistin-resistant Enterobacterales, Carbapenem-resistant / colistin- resistant
1640 *Acinetobacter baumannii*, Carbapenem-resistant *Pseudomonas aeruginosa* and other emerging MDR
1641 or XDR pathogens including MRSA ranged from 30 – 200 Euro per sample and parameter employing
1642 different PCR techniques, with an average of ca. 85 Euro per sample and parameter.

1643 Prices for untargeted ('shotgun') sequencing of all ('meta-') microbial genomes present in untreated
1644 wastewater samples (metagenomics) ranged from 300 to 4700 Euro with an average cost of ca. 1950
1645 Euro per sample.

Getting in touch with the EU

In person

All over the European Union there are hundreds of Europe Direct centres. You can find the address of the centre nearest you online (european-union.europa.eu/contact-eu/meet-us_en).

On the phone or in writing

Europe Direct is a service that answers your questions about the European Union. You can contact this service:

- by freephone: 00 800 6 7 8 9 10 11 (certain operators may charge for these calls),
- at the following standard number: +32 22999696,
- via the following form: european-union.europa.eu/contact-eu/write-us_en.

Finding information about the EU

Online

Information about the European Union in all the official languages of the EU is available on the Europa website (european-union.europa.eu).

EU publications

You can view or order EU publications at op.europa.eu/en/publications. Multiple copies of free publications can be obtained by contacting Europe Direct or your local documentation centre (european-union.europa.eu/contact-eu/meet-us_en).

EU law and related documents

For access to legal information from the EU, including all EU law since 1951 in all the official language versions, go to EUR-Lex (eur-lex.europa.eu).

EU open data

The portal data.europa.eu provides access to open datasets from the EU institutions, bodies and agencies. These can be downloaded and reused for free, for both commercial and non-commercial purposes. The portal also provides access to a wealth of datasets from European countries.

1647

1648

1649

Science for policy

The Joint Research Centre (JRC) provides independent, evidence-based knowledge and science, supporting EU policies to positively impact society



EU Science Hub

[Joint-research-centre.ec.europa.eu](https://joint-research-centre.ec.europa.eu)



Publications Office
of the European Union